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Norsk sammendrag – Norwegian summary 
 
 
Det har vært økende interesse rundt mulige helsegevinster ved å øke vitamin D-nivået i 
befolkningen. I data fra Tromsøundersøkelsen studerte vi sammenhengen mellom vitamin D-
nivå i blodet og risiko for senere å utvikle type 2 diabetes hos totalt 6119 personer. Risikoen var 
omtrent doblet blant den fjerdedelen som hadde lavest vitamin D-nivå sammenlignet med den 
fjerdedelen som hadde høyest nivå. Dette kunne hovedsakelig forklares ved at de med lavest 
vitamin D-nivå også hadde høyere kroppsmasseindex.  
Når vi deretter sammenlignet 52 personer med høye og 108 personer med lave vitamin 
D-nivåer, fant vi gunstigere nivåer av sukker og fett i blodet hos de med høye vitamin D-nivåer. 
Allikevel var det ingen bedring av disse verdiene i gruppen med lave vitamin D-nivåer etter å 
ha gitt vitamin D i høy dose (ca 150 mikrogram eller 6000 Internasjonale Enheter per dag) 
sammenlignet med placebo i seks måneder. I en annen studie sammenlignet vi standard dose 
vitamin D (800 Internasjonale Enheter) med slik høydose vitamin D hos 297 kvinner med 
redusert beintetthet. Begge dosene bedret eller opprettholdt beintettheten uten noen sikker 
forskjell mellom gruppene. Våre arbeider gir derfor ikke grunnlag for å anbefale bruk av 
vitamin D i høye doser. Ytterligere studier er nødvendige for å avklare det ideelle nivået av 
vitamin D.  
Videre har vi påvist at røyking kan påvirke målemetoder for vitamin D, noe som er 







There has been a large interest in possible beneficial health effects of increasing the vitamin D 
(as measured by 25-hydroxyvitamin D (25(OH)D)) levels in the population. Data from the 
Tromsø Study were used to assess the relation between serum 25(OH)D levels and the risk of 
subsequent type 2 diabetes in 6119 participants. This risk was approximately doubled in the 
lowest serum 25(OH)D quartile as compared to the highest quartile. This could to a large extent 
be explained by higher body mass index in the lowest quartile.  
When thereafter comparing 52 persons with high and 108 persons with low serum 
25(OH)D levels, we found more beneficial levels of glucose and lipid measures in those with 
high serum 25(OH)D levels. However, there was no improvement in the same measures in the 
low serum 25(OH)D group after six months supplementation with high dose vitamin D 
(approximately 150 mikrogram or 6000 international units/day) as compared to placebo. In 
another study, we compared one year treatment with standard dose of vitamin D (800 
international units) with the same high dose vitamin D among 297 women with reduced bone 
mineral density. Both doses improved or maintained bone mineral density with no differences 
between the groups. These results do not support the use of vitamin D in such high doses. 
Further studies are needed to assess the ideal level of serum 25(OH)D.  
We have further demonstrated that smoking might interfere with 25(OH)D laboratory 
analyses. This is important to consider in developing and validating such methods. 
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ANCOVA: analysis of covariance   
ANOVA: analyses of variance  
BMD: bone mineral density  
BMI: body mass index  
CI: confidence interval  
CT: computer tomography 
CTX-1: C-terminal telopeptid of type 1 collagen 
CV: coefficient of variation  
d: day   
DBP: vitamin D binding protein 
DEXA: dual X-ray absorptiometry  
ECLIA: electrochemiluminescence immunoassay 
FFA: free fatty acid 
FGF-23: fibroblast growth factor 23 
GC: gas chromatography  
h: hour 
HbA1c: glycated haemoglobin 
HOMA-IR: insulin resistance from the homeostasis model assessment 
HPLC: high performance liquid chromatography 
HR: hazard ratio 
IDS: Immuno Diagnostic System  
IPAQ: International Physical Activity Questionnaire  
ISI: insulin sensitivity index  
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This thesis originated from an interest in the ancient hormone vitamin D, which has attained a 
lot of focus the last couple of decades as a possible multifunctional and important contributor to 
health, and especially in the context of chronic lifestyle-related diseases. Thus, vitamin D 
deficiency has been associated with osteoporosis, cardiovascular disease, diabetes, cancer, 
autoimmune diseases and depression – to mention a few 1. In general, a person’s vitamin D 
level (measured as 25-hydroxyvitamin D (25(OH)D)) is a product of ultraviolet B (UVB) 
radiation from the sun, and to a less degree, from food. Our vitamin D status is therefore 
vulnerable to modern lifestyle with less physical activity and outdoor time, at the same time as 
overweight, contributing to vitamin D deficiency, increases. Many of the same lifestyle choices 
predispose both for vitamin D deficiency as well as for many diseases associated with vitamin 
D deficiency. Therefore, there are huge methodological challenges in defining whether vitamin 
D deficiency has a causal role in the development of these diseases. Thus, the key question is: 
Will increased vitamin D levels in the general population decrease the burden of chronic 
lifestyle related diseases, or is a high vitamin D level nothing but a marker of a healthy 
lifestyle? 
 Through the longitudinal, multi-purposed and population-based Tromsø Study, we had 
the opportunity to analyze serum 25(OH)D in sera stored from the 4th Tromsø Study in 1994-
1995, and to relate the 25(OH)D levels to subsequent occurrence of type 2 diabetes in an 
observational study. Results from such observational studies are important as hypothesis 
generators, but can not be used as final evidence for causal relations between vitamin D 
deficiency and the studied diseases. To go further, we also invited participants from the 6th 
Tromsø Study in 2008 based on their serum 25(OH)D measurements to study how these levels 
related to the regulation of glucose and lipid metabolism. Finally, we randomized the 
 12
participants with low serum 25(OH)D levels to receive either vitamin D or placebo for six 
months and then performed a new examination to see if and how the supplementation affected 
the measurements. As we were faced with laboratory difficulties regarding serum 25(OH)D 
measurements which were previously not described, a methodological validation study was 
necessary to perform.  
 Although focusing on a different chronic disease – osteoporosis – the last study included 
in this thesis also dealt with the question whether the vitamin D levels seen today, and 
accordingly, the recommended intake, are adequate for optimal health. Including 
postmenopausal women with low bone mineral density (BMD) and randomizing them to 
standard or high dose of vitamin D, the objective of the study was to see whether high dose was 
better than standard dose in improving BMD and reducing bone turnover.  
     The thesis will present these studies in detail, and try to discuss and integrate the 
methodological challenges and the findings into the current state of knowledge in the extensive 
field of vitamin D research.  
 
1.1 Vitamin D 
Vitamin D is a lipophil secosteroid that exists in two forms; ergocalciferol (vitamin D2) and 
cholecalciferol (vitamin D3) 
2. These two forms differ in one double-binding and one methyl 
group. While vitamin D2
 is found in vegetable sources like mushrooms, vitamin D3 can be 
found in animal sources like fat fish, cod liver oil, egg yolk and fortified food like dairy 
products 1. Vitamin D supplements might contain both forms, although in Norway, vitamin D3 
is almost exclusively used in over-the-counter vitamin D supplements.  
Importantly, the body itself has the ability to produce vitamin D3, when UVB radiation 
(wavelength 290-315 nm) reaches preformed 7-dehydrocholesterol in the skin. Previtamin D3 is 
then formed, which under normal temperature conditions isomerizes to form vitamin D3 
3. The 
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relative importance of the different vitamin D sources differs in and between populations due to 
different climatic conditions, cultural practices and dietary habits 4. In Tromsø, located at 69°N, 
sufficient UVB radiation for dermal vitamin D production is only available from the mid of 
March to the end of September 5. However, the use of sunbeds, sunny holidays and 
supplementation like cod liver oil, together with a traditionally high intake of marine food, 
might counteract the lower dermal production 6. Serum 25(OH)D levels have demonstrated 
high heritability, which seems to be at least as important as environmental factors in explaining 
variance in serum 25(OH)D levels 7. Thus, genome wide association studies have identified 
polymorphisms in genes coding for proteins involved in cholesterol metabolism (7-
dehydrocholesterol reductase), vitamin D hydroxylation (CYP2R1) and transport (vitamin D 
binding protein (DBP)) as important determinants of serum 25(OH)D levels 8.  
In the body, vitamin D is rapidly 25-hydroxylated in the liver to either 25-
hydroxyvitamin D2 (25(OH)D2) or 25-hydroxyvitamin D3 (25(OH)D3) (referred to as 25(OH)D 
if the distinction is of no importance). This enzymatic process is poorly regulated 9, but seems 
to be of first order magnitude when the substrate concentration is low (serum vitamin D below 
15 nmol/L, corresponding to 25(OH)D below 80-100 nmol/L), and zero order above (higher 
substrate concentrations) 10. Thus, excess vitamin D3 has been widely believed to be 
sequestered and stored in adipose tissue 1,2, which also might explain a consistently described 
inverse relation between body mass index (BMI) and serum 25(OH)D 11,12. However, in a 
recently published study using vitamin D3 50,000 IU/week (w), resulting in final serum 
25(OH)D of 125 nmol/l, the authors estimated that less than one fifth of the administered 
vitamin D3 actually was sequestered in fat tissue, indicating that most of it was metabolically 
consumed 13. The half-life of 25(OH)D is two - three weeks, and because of its stability, and its 
reflection of vitamin D from all sources, this metabolite is currently regarded the most suitable 
biomarker for a person’s vitamin D status 9.  
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Activation of 25(OH)D requires further hydroxylation to 1,25-dihydroxyvitamin D 
(1,25(OH)2D). This hydroxylation occurs mainly in the kidneys, where the enzyme, 1-alfa-
hydroxylase, is under tight control from parathyroid hormone (PTH), which upregulates the 
process, and fibroblast growth factor 23 (FGF-23) which downregulates it 9. The main stimulus 
for this regulation is the serum concentration of ionized calcium, which, when low, increases 
PTH secretion from the parathyroid glands. The resulting increase in 1,25(OH)2D leads to 
increased gastrointestinal and renal calcium absorption, as well as mobilization of calcium from 
bone through increased osteoclast activation. Also, gastrointestinal phosphate absorption is 
increased. Likewise, high serum 1,25(OH)2D and phosphate levels stimulate release of  FGF-23 
from osteocytes and osteoblasts, which through downregulation of 1-alfa hydroxylase and 
increasing transformation of 1,25(OH)2D to the less active form 24,25-dihydroxyvitamin D 
(24,25(OH)2D), diminish calcium absorption and also increases phosphaturia. These processes 
ensure the body with serum calcium levels within narrow physiological ranges, providing stable 
extracellular calcium available for intracellular calcium, important particularly for nerve and 
muscle function, as well as optimal conditions for normal bone homeostasis and blood 
coagulation 14.  
Activation of vitamin D does not only occur in the kidneys. The enzyme 1-alfa-
hydroxylase is present in numerous other tissues and cells, providing opportunities for 
extrarenal hydroxylation. This hydroxylation is not regulated by PTH, but by local growth 
factors and cytokines 9, and it is believed that sufficient substrate, 25(OH)D, is of greater 
importance there than in the kidneys, where PTH drives 1,25(OH)2D production across a broad 
range of 25(OH)D levels, and only at low substrate levels begins to diminish 15. Locally 
produced 1,25(OH)2D does probably not enter the circulation in large amounts, but works 
locally in an autocrine or paracrine manner 9. Thus, the local 1,25(OH)2D levels are probably 
better reflected by serum 25(OH)D than by serum 1,25(OH)2D, which in addition has a short 
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half-life (2-4 hours (h)) 2. The importance of this system is however highly unsettled, as is its 
regulation 9.  
Vitamin D in all forms is transported in blood coupled to DBP. This protein’s affinity is 
stronger to 25(OH)D than to the active form 1,25(OH)2D. The effect of vitamin D on the target 
cells are mediated through the vitamin D receptor (VDR), where the affinity is opposite, being 
much stronger to 1,25(OH)2D. VDR is a member of the steroid receptor family, and as such, 
acts as a ligand-activated transcription factor 9. A vitamin D responsive element is found in 
many genes involved mainly in bone and calcium metabolism, inflammation, and cell growth 
and differentiation 16, and it has been reported that vitamin D affects the transcription of more 
than 200 genes, either directly or indirectly 1. There are also evidence for non-genomic rapid 
effects of 1,25(OH)2D which seem to involve other receptors, but the nature and significance of 
these receptors are not completely understood 9.  
The different vitamin D metabolites are finally catabolized to several compounds that 
are excreted via the biliary and renal system, among them calcitroic acid and lactones 1,2. The 
regulation of the first step in this process, 24-hydroxylation of either 25(OH)D or 1,25(OH)2D, 
is tightly regulated in a reciprocal way of 1-alfa hydroxylase 9. Fig 1 shows vitamin D3 




Dusso A S et al. Am J Physiol Renal Physiol 2005;289:F8-
F28
©2005 by American Physiological Society  
Fig. 1 Vitamin D3 synthesis, activation, and catabolism
9. Used with permission. 
 
1.2 Vitamin D levels 
The definition of an optimal vitamin D status remains a challenge. Roles of biomarkers in 
nutritional surveillance can be divided into markers of supply, markers of function, markers of 
intermediate endpoint or markers of disease 17. Serum 25(OH)D is regarded the most suitable 
marker of supply. However, there is no international consensus regarding reference range for 
serum 25(OH)D concentrations, neither for how this range should be defined. Setting a 
reference range using population based cutoffs of 5 and 95% will depend on the general 
vitamin D status in that particular population, and will not necessarily reflect the physiological 
normal range. A more historical approach has been to assume that the body’s physiology is 
adapted to an outdoor life with abundant UVB exposure 18. Thus, mean serum levels of outdoor 
workers like farmers or lifeguards have been used as a proxy of a “natural” serum 25(OH)D 
level, ranging from 135 to 163 nmol/l 19.  
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As a functional outcome, several authors have studied the inverse relation between 
serum 25(OH)D and PTH. The level where serum PTH stops decreasing has been suggested as 
the threshold for sufficiency. Notably, this approach has not given consistent results, as this 
threshold has been reported somewhere from 25 nmol/l 20 to 110 nmol/l 21. Differences in 
calcium intake between the study populations and methodological problems with PTH and 
25(OH)D measurements might explain some of this discrepancy. Also, in spite of low serum 
25(OH)D levels, a substantial portion of patients may have a “blunted” PTH response and 
conversely lower serum calcium levels. The mechanism and significance of this is not clear, but 
low intracellular magnesium levels have been suggested as a possible mechanism 22.  
Using intermediate endpoints for diseases like BMD, insulin sensitivity, or markers of 
innate immunity is complex, as these endpoints are affected by a number of  factors other than 
vitamin D. The index disease of vitamin D deficiency, rickets in children and osteomalacia in 
adults, are seldom seen when serum 25(OH)D exceeds 20 nmol/l 23. However, rickets in 
children with higher vitamin D levels have been reported in the state of calcium deficiency 24,25. 
The prevalence of rickets can nonetheless be regarded an index of severe vitamin D deficiency 
in a population.  
Definition of degrees of vitamin D sufficiency from the Norwegian guidelines from 
2006 is shown in Table 1. The aim of the guidelines is to achieve a serum 25(OH)D level above 
50 nmol/l in as many as possible with nobody below 25 nmol/l 26. To ensure that adequate 
levels are achieved in the general population, a vitamin D intake of at least 300 IU for those 
aged 2-60 years, and 400 IU for those younger than two years or older than 60 years, is 





Table 1 Threshold values for vitamin D status  
25(OH)D in serum or plasma__________  Description____________________ 
>50 nmol/l* sufficient 
25-50 nmol/l suboptimal 
12.5-25 nmol/l deficiency 
<12.5 nmol/l severe deficiency 
* Serum 25(OH)D should not exceed 200 nmol/l for a longer period of time.  
Slightly modified from Meyer HE et al (2006) National Nutrition Council 26. Used with permission.   
 
 
1.3 Vitamin D measurements 
Being highly hydrophobic and tightly protein-bound, measuring serum 25(OH)D is challenging 
28,29. Furthermore, an assay should ideally measure both the 25(OH)D2 and 25(OH)D3 forms, 
especially in populations where supplementation and fortification consist of both. Several 
methods are available today, and they can mainly be divided into two main groups: 
immunoassays and chromatographic methods 28. Both depends on the separation between the 
DBP and the 25(OH)D molecule. In the immunoassays, an antibody will then recognize 
25(OH)D, and the quantification relies on some sort of enzymatic, radioactive or 
electrochemilumnicent marker coupled to the antibody. These methods might be more or less 
fully automated, which make high-throughput possible. However, their ability to recognize the 
two forms 25(OH)D2 and 25(OH)D3 differs, and the methods are prone to performance changes 
over time 29. The chromatographic methods use either gas chromatography (GC) or high 
performance liquid chromatography (HPLC), which again can be coupled to a mass 
spectrometry (MS) method. The advantages of these methods are higher accuracy with no 
cross-reactions, and 25(OH)D2 may easily be separated from 25(OH)D3. However, the 
equipment is expensive, it requires trained and experienced personnel, and through-put is much 
lower than for the automated immunoassays 28.  
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A general problem with serum 25(OH)D measurements is the lack of international 
standardization with the use of a common global calibrator, which makes results from different 
studies difficult to compare directly 29. This adds to the confusion regarding defining thresholds 
for optimal serum 25(OH)D levels. Several attempts are being made to improve the quality and 
comparability of these measurements 29,30.  
Validation of serum 25(OH)D assays is usually performed by comparing with other 
available methods, as there is no generally accepted gold standard method 29. This is usually 
done irrespective of the characteristics of the blood donors 31-33. Own preliminary results from 
the 4th Tromsø Study surprisingly showed higher serum 25(OH)D levels in smokers than in 
non-smokers, which was not consistent with prevailing literature 34-36. Smoking increases risk 
of both osteoporosis 37 and diabetes 38. With the possible influence smoking may have on serum 
25(OH)D measurements, it is therefore an important factor to consider in studies on these 
diseases, and also in the validation of the assays used for determining serum 25(OH)D. 
 
1.4 Type 2 diabetes 
The prevalence of type 2 diabetes is increasing worldwide, with an estimated doubling of 
persons with the disease from year 1995 to year 2025 39. As a chronic condition, type 2 diabetes 
contributes to increased risk of microvascular and macrovascular complications including 
cardiovascular disease 40. Thus, the disease has both individual costs through decreased quality 
of life and huge economical costs for the society.  
     The development of type 2 diabetes is considered a result of increased peripheral insulin 
resistance combined with decreased insulin secretion from the beta-cells in pancreas 40. While 
the body’s capacity for insulin secretion is predominantly genetically determined, the insulin 
resistance is considered mainly a result of lifestyle 41,42, with central obesity, inactivity, aging, 
overeating and increased levels of free fatty acids (FFA) being the main risk factors 39. Thus, 
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we are born with different vulnerability for insulin resistance, which explains why some might 
tolerate obesity without developing type 2 diabetes through a compensatory increase in insulin 
secretion, while others do not have this ability. Nonetheless, increased insulin resistance leads 
to slightly increased blood glucose values within the normal range, which over time may 
damage the beta cells in a phenomenon called glucotoxicity 39,40. A similar phenomenon, called 
lipotoxicity, is a result of increased levels of FFA, which originate from insulin resistant 
adipocytes 40. This results in a diminished beta cell mass over time, leading to a decrease in the 
insulin secretory capacity.  
 
1.5 Vitamin D and type 2 diabetes 
In vitro and animal studies have revealed several aspects of diabetes development that might be 
affected by vitamin D. First, both VDR and 1-alfa-hydroxylase are present in beta cells, 
allowing local 1,25(OH)2D production and function 
43,44. Secondly, a VDR responsive element 
on the human insulin gene promoter has been identified 45. Accordingly, several 46-49, but not all 
50 experimental studies have provided evidence for an independent role of vitamin D in the 
insulin secretory capacity of the beta cells, suggesting that vitamin D affects glucose-mediated 
insulin secretion rather than fasting insulin levels 47,48. In vitro, 1,25(OH)2D has been reported 
to increase the expression of the insulin receptor and enhance insulin-mediated glucose 
transport 51, indicating a role also in insulin sensitivity. Finally, the systemic inflammation 
accompanying insulin resistance and diabetes development might also be dampened by vitamin 
D through several mechanisms 52. 
Human observational studies have predominantly supported these experimental results. 
In a prospective study of more than 83,000 women in the Nurses’ Health Study, those with the 
highest intake of vitamin D as well as calcium experienced a 33% decrease in subsequent risk 
of diabetes 53. In studies based on serum measurements, thereby including also sun-derived 
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vitamin D, inverse associations between serum 25(OH)D and measures of glucose levels 54-59, 
insulin resistance 56,58-62 and diabetes 63-66 have been reported.  
With few exceptions 53,56,65,67, these studies have been cross-sectional, excluding 
temporality as an evidence of causality. There have also been few properly designed 
intervention trials, and as recently reviewed, the results are conflicting 68. Limitations of the 
studies include small samples, lack of proper control groups, short intervention periods, indirect 
measurements of insulin sensitivity, in addition to heterogeneity regarding dosing regimens 68. 
As some of the data originate from post hoc analyses of osteoporosis intervention trials, the 
effect of vitamin D might be hard to separate from the effect of calcium.  
 
1.6 Bone metabolism 
The skeleton is a highly metabolic tissue which provides the best compromise between strength 
and stability (stiffness) on one hand, as opposed to functional mobility on the other hand. Other 
tasks are protection of internal organs, production of blood cells in the bone marrow, and it also 
constitutes the body’s main store of different minerals like calcium and phosphate. The skeletal 
tissue consists of principally three different cell types; bone-resorbing osteoclasts, and bone 
forming osteoblasts, which when surrounded by mineralized connective tissue finally become 
osteocytes; all offering important tasks in maintaining a functioning skeleton. The extracellular 
matrix consists predominantly of the mineral calciumhydroxyapatite and type 1 collagen. There 
are two types of bone tissue, cortical (compact) bone which is found especially in the shafts of 
the long bones and the surface of flat bones, and trabecular (cancellous) bone which is located 
in vertebrae, in the end of long bones and the inner part of flat bones 69.   
The skeleton is undergoing lifelong renewal in form of dynamic bone remodelling. 
During ten years, the adult skeleton is completely remodelled 70. The remodelling process 
follows a certain pattern in the osteon (the functional unit of cortical bone), where bone 
resorption, performed by osteoclasts, is followed by osteoid production by the osteoblasts. This 
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is governed by an orchestra of endocrine, neuronal and local factors, where the osteocytes exert 
a major role in defining where and when bone remodelling should take place. Central in this 
process is the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B ligand 
(RANK)/RANK ligand (RANKL) system, where RANKL released from the osteoblasts reacts 
with the receptor RANK at the osteoclast precursor and induce osteoclast formation and 
activation, leading to bone resorption. OPG, on the other hand, acts as a soluble decoy receptor, 
where binding to RANKL inhibits osteoclast stimulation 70. Bone resorption is followed in time 
and space by bone formation, where osteoid is laid down by the osteoblasts 69. Finally, the 
osteoid is mineralized in two stages; early mineralization, which occurs within a few days, and 
secondary mineralization which may take more than six months 71. 
After increasing bone mass through childhood and adolescence, a peak bone mass is 
reached in early adult life (20-30 years). Bone resorption and formation are thereafter balanced, 
resulting in minimal cortical bone loss until menopause in women, and until 60 years in men 72. 
Trabecular bone loss is reported to start as early as in the third decade in both sexes, and in 
addition accelerates during perimenopause in women 73. Sex steroids have proapoptotic effects 
on osteoclasts but antiapoptotic effects on osteoblasts and osteocytes, accordingly, menopause 
leads to an imbalance between bone resorption and formation 69,70,72. Together with decreased 
calcium absorption from the gut and reabsorption in the kidneys, this accounts for lower 
mineral content and bone strength 74. As women in general obtain a lower peak bone mass in 
young adulthood, and experience a larger loss due to the influence of rapid sex steroid hormone 
loss, these factors explain why osteoporosis is regarded a women’s disease. However, 
osteoporosis may also affect men, as illustrated by data from Sweden showing that almost one 
out of two women and one out of four men will experience an osteoporotic fracture throughout 
life 75.    
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Presently, the diagnosis of osteoporosis depends on BMD measurements, where a T-
score (standard deviations (SD) above or below the mean of healthy young women) ≤ -2.5 
defines osteoporosis, and a T-score ≥ -1.0 is regarded as normal. Those in between are defined 
as having osteopenia 76.  
 
1.7 Vitamin D and osteoporosis 
In addition to its role of providing calcium to the mineralization of bone, 1,25(OH)2D is also 
involved locally in several steps of the bone turnover process. The exact role of 1,25(OH)2D in 
bone is, however, complex and not fully understood 71. Both the enzyme 1-alfa-hydroxylase 
and the VDR are present in bone cells 77, and in vitro experiments suggest a role of 1,25(OH)2D 
in enhancing the coupling and communication between osteoclasts and osteoblasts 78. In vitro 
experiments have also demonstrated that treatment with 1,25(OH)2D reduces impairment of 
human osteoblast functions during aging 79, and that locally produced 1,25(OH)2D is important 
in differentiation of osteoblasts from human marrow stromal cells 80. By inducing RANKL, 
1,25(OH)2D further stimulates osteoclast formation and differentiation; the latter down-
regulating bone resorption 78. Also, by increasing OPG secretion from mature osteoblasts, bone 
resorption is inhibited 81. Although very high doses of 1,25(OH)2D increase bone resorption in 
vitro, physiological doses are believed to have the opposite effect by inhibiting PTH-induced 
bone resorption 82. 
Still, the role of vitamin D in osteoporosis is controversial. Vitamin D together with 
calcium is generally considered first line therapy for people at risk of osteoporotic fractures 83. 
A positive association between vitamin D intake and/or serum 25(OH)D levels and BMD has 
been reported in several studies 84-88. However, no association was found in other populations 
89-91. The reasons for this discrepancy remain unclear. It has been suggested that in a population 
with generally good vitamin D and calcium status, vitamin D does not play a major role in bone 
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health 90,91, although in some of the studies showing an association, mean serum 25(OH)D 
concentrations were generally high (102 nmol/L in women and 109 nmol/L in men) 86,88.   
Similarly, cohort studies have not established a consistent association between basal 
serum 25(OH)D levels and later fracture risk. Thus, no association was seen in some studies 
90,92, while two longitudinal American studies reported higher risk of hip fracture with lower 
baseline serum 25(OH)D levels 93,94. A third study reported no association between hip fracture 
risk and serum 25(OH)D levels, while lower serum 1,25(OH)2D was associated with an 
increased risk of hip fracture 95. 
Results from clinical studies on the effect of vitamin D on fracture risk are also 
conflicting, with some finding an effect 96-98, and others not 99-101. Several meta-analyses have 
been published on the effect of vitamin D with or without calcium supplementation on the risk 
of fracture 102,103. Although with some methodological differences, one may conclude that 
vitamin D given alone does not prevent fractures, while vitamin D combined with calcium has a 
modest fracture reducing effect. The interpretation of the results has been complicated by 
problems with low compliance to medication, the use of vitamin D2 which might be less potent 
than vitamin D3 
13, and low vitamin D dosages (400 international units (IU)/d). Thus, studies 
reaching a mean 25(OH)D level >75nmol/l, which requires dosages of at least 7-800 IU/d, 
show a significant effect on hip fracture, with a relative risk (RR) (95% confidence interval 
(CI)) of 0.74 (0.61-0.88) compared to placebo 104.  
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2. Aims of the thesis 
 
The overall aim of the thesis was to explore the relation between serum 25(OH)D and 
metabolic disorders in order to elucidate whether higher levels of serum 25(OH)D could have 
beneficial health effects. Specifically, the aims of the subprojects were to:  
 
• Validate 25(OH)D measurement methods with special emphasize on the effect of 
smoking. (Paper I) 
•  Study the association between serum 25(OH)D levels at baseline and incident type 2 
diabetes during 11 years of follow-up in a population-based study. (Paper II) 
• Compare insulin sensitivity, secretion and lipid profiles between subjects with sufficient 
and insufficient levels of serum 25(OH)D, and to assess whether supplementation with 
vitamin D in the insufficient group affects these measures. (Paper III) 
• Study whether high dose of vitamin D is better than standard dose of vitamin D in 
improving BMD and bone turnover markers in postmenopausal women with low 
BMD. (Paper IV) 
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3. Study population and methods 
 
3.1 Study populations 
 
3.1.1 Papers I-III 
The data and/or inclusion of participants to the studies described in Paper I-III originated from 
the Tromsø Study. This population-based ongoing study started in 1974 in order to explore the 
reasons for the high cardiovascular mortality among men in Northern Norway. Since then, the 
study has expanded to include both genders, and a broad multipurpose approach has been 
applied, opening for research on a number of life-style related diseases 105. Table 2 shows 
examination years, age groups included, and attendance rates.  
In the 4th Tromsø Study, performed in 1994-95, all individuals living in the municipality 
of Tromsø aged 25 years or older were invited to participate. A total number of 27,158 persons 
attended the first visit, providing an attendance rate of 77% among eligible inhabitants. All men 
aged 55-74 years, all women aged 50-74 years, and a sample of 5-10% of the remaining age 
groups between 25 and 84 years were invited to undergo a more extensive clinical examination 
(second visit), and 7965 persons, or 78% of those invited, attended 105. All participants who 
attended this second visit had a blood sample taken and stored, and these sera were thawed and 
analyzed for 25(OH)D during spring 2008. 
The 6th Tromsø Study was performed in 2007-8 and the following groups were invited: 
those who participated in the second phase of the fourth survey (1994-95), a random 10% 
sample of subjects 30-39 years old, all subjects 40-42 and 60-87 years old, and a random 40% 
sample of subjects 43-59 years old, In total, 19,762 subjects were invited to the 6th Tromsø 
Study, and 12,984 subjects (65.7%) attended 105. Serum 25(OH)D was measured in all 
participants.   
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Table 2 The Tromsø Study; examination year, age groups included and attendance rate. Number of subjects (N) and mean  
age in the six different surveys are given according to gender and attendance 
 
  Men Women 
   Attendees Non-attendees  Attendees Non-attendees 
 Age group % attendance N Age N Age % attendance N Age N Age 
Tromsø 1 (1974) 20-49 74.4 6595 33.7 2271 30.2 -     
Tromsø 2 (1979-80) 20-54 a 73.8 8477 35.7 3004 31.3 81.8 8144 32.9 1815 28.7 
Tromsø 3 (1986-87) 12-67 b 71.7 10,963 37.6 4318 32.5 79.0 10,863 35.4 2882 29.9 
Tromsø 4 (1994-95) 25-97 69.6 12,865 46.6 5615 40.9 74.9 14,293 47.2 4785 44.1 
Tromsø 5 (2001-02) 30-89 75.7 3511 59.9 1125 46.0 80.8 4619 59.4 1098 50.8 
Tromsø 6 (2007-08) 30-87 62.9 6054 57.5 3571 54.5 68.4 6930 57.5 3207 58.1 
a  20-49 in women.   b All men aged 20-61 and women aged 20-56 were invited  
Slightly modified from Jacobsen BK (2011) Int J Epidemiol 105. Used with permission.  
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In Paper I we included all participants with valid serum 25(OH)D measurements and 
available data on smoking from the 4th Tromsø Study. We also included randomly selected 
participants from the 6th Tromsø Study who accepted an invitation to participate in a 
validation study of vitamin D measurements. Based on self-reported smoking data in the 
Tromsø Study questionnaire, they were regarded current smokers (defined as a person 
reporting smoking at least 5 cigarettes per day (d)) or non-smokers (defined as never smoked, 
or more than five years since quitted smoking), and a similar number of smokers and non-
smokers were included.  
In Paper II we included participants in the 4th Tromsø Study with valid serum 25(OH)D 
and glycated haemoglobin (HbA1c) measurements in the baseline examination at the Tromsø 
Study 1994-95. Participants with baseline HbA1c  ≥ 6.5%, those who reported or were 
registered with diabetes at baseline, were registered as moved before baseline, or had missing 
information on any of the variables used in the models (BMI, physical activity and smoking), 
were excluded from the analyses.  
In Paper III we invited participants from the 6th Tromsø Study based on their serum 
25(OH)D measurements to a follow-up study. The analyses from the validation study in Paper 
I were ongoing during the inclusion period, and we therefore chose not to invite smokers to 
avoid interference with the results. Participants with serum 25(OH)D between the 5-10 
percentile (low serum 25(OH)D, cases) or between the 80-95 percentiles (high serum 
25(OH)D, controls), were invited, and low or high serum 25(OH)D levels were confirmed in 
new serum samples before inclusion. BMI is inversely associated with serum 25(OH)D 12 and 
also a main contributor to insulin sensitivity 39. To avoid confusion on whether a difference 
between cases and controls were dependent on differences in BMI only, participants were 
invited based on BMI data, age and gender from the 6th Tromsø Study in order to achieve a 
fairly equal distribution between cases and controls. There was, however, no head-to-head 
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matching. Exclusion criteria were diabetes mellitus, acute myocardial infarction or stroke last 
12 months, cancer last five years, steroid use, serum creatinine ≥ 130 µmol/l (males) or ≥ 110 
µmol/l (females), possible primary hyperparathyroidism (plasma PTH >5.0 pmol/l combined 
with serum calcium >2.50 mmol/l), sarcoidosis, systolic blood pressure >175 mmHg or 
diastolic blood pressure >105 mmHg. Pregnant or lactating women, and women in fertile age 
(<50 years) reporting no use of contraception, were not included. 
 
3.1.2 Paper IV 
In Paper IV, we included 50-80 years old postmenopausal women with a T-score ≤-2.0 in 
total hip or lumbar spine (L2-4). The participants should not have used hormone replacement 
therapy or other therapy affecting bone remodelling during the last 12 months before 
enrolment. Further exclusion criteria were use of steroids, renal stone disease, systolic blood 
pressure >175 mm Hg or diastolic blood pressure >105 mm Hg, serum creatinine >110 
µmol/l, suspected primary hyperparathyroidism (serum calcium >2.55 mmol/l; serum calcium 
>2.50 mmol/l combined with plasma PTH >5.0 pmol/l; or serum calcium >2.45 mmol/l 
combined with plasma PTH >7.0 pmol/l), or chronic diseases like ischemic heart disease, 
diabetes, granulomatous disease or cancer.   
Participants were recruited from the outpatient clinic; through advertisement; and from 
other completed clinical studies where BMD was measured. These other studies included the 
6th Tromsø Study; the NATTO Study (studying the effect of vitamin K on bone loss) 106; and 






Self-administrated questionnaires were filled out in all the Tromsø Study surveys. In Paper I 
and II we used the following questions regarding smoking: “Do you smoke cigarettes daily?” 
(yes/no), “For previous or current smokers: How many cigarettes do you, or did you smoke 
daily? (handrolled + factory made)”, and “If you currently smoke, or have smoked before, 
how many years in all have you smoked daily?”. We also used the smoking variable “If you 
previously smoked daily, how long is it since you stopped (years)?” Subjects answering yes to 
“Do you smoke a pipe daily?” or “Do you smoke cigars/cigarillos daily?” were coded as 
current smokers. In Paper III, the question “Do you/did you smoke daily” was used to exclude 
current smokers (ticking “yes, now”) from being invited. 
Data on physical activity used in Paper I and II was registered in the 4th Tromsø Study 
through the following questions: 1.“Light activity (not sweating or out of breath): How has 
your physical activity in leisure time been during the last year? Think of your weekly average 
for the year. Time spent going to work count as leisure time (h/w).” 2. “Vigorous physical 
activity (sweating/out of breath): How has your physical activity in leisure time been during 
the last year? Think of your weekly average for the year. Time spent going to work count as 
leisure time (h/w).” The response alternatives for both questions were as follows: 1 = none, 2 
= <1 h, 3 = 1-2 h, 4 = 3 h or more. In Paper I, the main purpose was to adjust for outdoor 
time. The answers were therefore recoded into 0-1-2-3 h, and a physical activity score was 
calculated by adding together hours of light and vigorous physical activity/w. In Paper II, we 
wanted to adjust for both outdoor time and the effect of physical activity on diabetes 
development, and each hour of vigorous activity was therefore given a double score compared 
to each hour of light activity, up to a maximum of nine points.  
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Data on physical activity used in Paper III as a proxy for outdoor time was obtained 
through the following question in the 6th Tromsø Study: “Exercise and physical exertion in 
leisure time. If your activity varies much, for example between summer and winter, then give 
an average. The questions refer only to the last twelve months.” The following response 
categories were possible: level 1: reading, watching television, or engaging in sedentary 
activities; level 2: at least 4 h a week walking, bicycling, or engaging in other types of 
physical activity; level 3: at least 4 h a week exercising to keep fit and participating in 
recreational athletics; and level 4: regular, vigorous training or participating in competitive 
sports several times a week. 
In Paper I and II, vitamin D supplementation was defined as use of cod liver oil 
(yes/no) and/or multivitamins containing vitamin D (yes/no). In Paper III, data on fat fish 
intake was self-reported using the following alternatives: 1: 0-1 times/month; 2: 2-3 
times/month; 3: 1-3 times/w; 4: 4-6 times/w; and 5: 1-2 times/d. The following variables were 
in addition registered at screening: Medical history, current medication use, use of cod liver 
oil last year (whole year every day; whole year, not daily; winter every day; or winter, not 
daily), other supplements (name), sunny holidays last three months, times using sunbeds last 
year, number of glasses of milk and sandwiches with cheese/d, and servings of yoghurt/w. 
Women were asked if they had regular menstruation, and accordingly; use of contraception or 
year of menopause. Due to content of nut oil in the study medication, all participants were 
asked specifically if they had experienced nut allergy.  
In Paper IV the following information was obtained at screening: Medical history, 
current medication use, nut allergy, previous use of estrogen and bisphosphonates, current or 
previous smoking, year of menopause, times using sunbed last year, sunny holidays the 
previous 12 months and time spent outdoor during the period of possible UVB-mediated 
vitamin D production in the skin at the study location (69ºN) 5. Hence, the participants were 
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asked about mean time spent outdoor between 10 AM and 3 PM in March-April and 
September, and between 8 AM and 8 PM in May-August. At baseline the participants filled in 
a food frequency questionnaire 108 and a questionnaire on physical activity (International 
Physical Activity Questionnaire (IPAQ), short last 7 days self-administered format) 109. Thus, 
intakes of calcium and vitamin D were calculated, and physical activity was transformed to 
metabolic equivalent (MET)-minutes (min)/w and IPAQ categories according to IPAQ 
guidelines.  
 
3.2.2 The end point registry 
In Paper II we used data on diabetes from the Tromsø Study’s endpoint registry. The 
University Hospital of North Norway is the only hospital in Tromsø, and admissions to other 
hospitals are unlikely because of long distances. The Tromsø Study is therefore able to follow 
attendants who have taken part in the surveys with regard to incident cases of several 
endpoints, which includes cardiovascular disease, diabetes and non-vertebral fractures. 
Adjudication of first-ever cases of these conditions is performed by independent endpoint 
committees, and each case is reviewed separately 105. Emigration from the municipality or 
from Norway and date of death are registered by the National Population Register of Norway. 
A detailed description of definition and ascertainment of type 2 diabetes is presented in  
Paper II.  
 
3.2.3 Physical measurements 
Height and weight were measured wearing light clothing and no shoes. Height was rounded to 
the nearest 0.5 cm, and weight in kg was recorded with one decimal.  
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3.2.4 Blood samples 
 
Serum 25(OH)D was measured in sera from the 4th and 6th Tromsø Study by an 
electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics®, Mannheim, 
Germany), using an automated clinical chemistry analyser (Modular E170, Roche 
Diagnostics®, Mannheim, Germany) 31. The total analytical coefficient of variation (CV) for 
the 25(OH)D3 assay was 7.3% as recorded by measuring a donor control (65.0 nmol/L) 
consecutively during the analytical period using a quality management programme (QM™, 
Tieto Enator, Helsinki, Finland). This was in accordance with the total analytic precision of 
≤7.8% as reported by the producer. The cross-reactivity with 25(OH)D2 was <10% and the 
lower detection limit was 10 nmol/L. The sera from the 4th Tromsø Study had been stored 
frozen at -70ºC. Serum 25(OH)D levels have been demonstrated to be stable in spite of 
multiple freeze-thaw cycles 110. 
In Paper I, the main purpose was to validate the ECLIA method against other available 
methods. In addition to ECLIA, we therefore used two liquid chromatography (LC)-MS/MS 
methods, one HPLC method and two different radioimmunoassay methods (RIA) (DiaSorin 
and Immuno Diagnostic Systems (IDS)) in a substudy. One of these LC-MS/MS methods, 
developed at the Hormone Laboratory, Haukeland University Hospital, Bergen, Norway was 
also used when analyzing baseline and final serum 25(OH)D levels in Paper III and IV. This 
method includes extraction of serum with n-hexane:isopropanol and injection into an isocratic 
HPLC system coupled with a MSciex API 3000 mass spectrometer (Carlsbad, CA, USA) 
equipped with an electrospray source. There is no known interference from other substances, 
including no cross-reaction with vitamin 25(OH)D2.   
Bone turnover markers and 1,25(OH)2D used in Paper IV were analysed at the 
Hormone Laboratory, Oslo University Hospital. The bone resorption marker C-terminal 
telopeptid of type 1 collagen (CTX-1) was measured in serum by an enzyme-linked 
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immunosorbent assay (IDS, Herlev, Denmark), reference range for postmenopausal women 
was <1.35 µg/l according to the producer. The bone formation marker N-terminal propeptid 
of type 1 procollagen (P1NP) in serum was measured by RIA (Orion Diagnostics, Espoo, 
Finland); reference range for postmenopausal women was 16-96 µg/l according to the 
producer. 1,25(OH)2D was measured by RIA (DiaSorin, Stillwater, MN, USA); reference 
range 42-169 pmol/l.  
The other laboratory analyses were performed consecutively at the Department of 
Medical Biochemistry at the University Hospital of North Norway. The only exception was 
plasma PTH from the 4th Tromsø Study (used in Paper I and II), which was measured in 
thawed stored samples in a subgroup (47%) in 2001 using an automated clinical chemical 
analyser (Immulite 2000, Siemens Healthcare Diagnostics, Los Angeles, CA, USA), with a 
reference range of 1.1-6.8 pmol/L (≤50 years) and 1.1-7.5 pmol/L (>50 years). The laboratory 
methods for the other analyses used are described in Paper I-IV.  
 
3.2.5 Hyperglycemic clamp 
Insulin sensitivity and secretion were measured in Paper III as previously described using a 
three-hour hyperglycemic clamp technique 60,111,112. Under a standardized steady state 
hyperglycemic condition where plasma glucose is held constantly at 10 mmol/l, measures of 
total (hepatic and peripheral) insulin sensitivity are provided. The insulin sensitivity index 
(ISI) is calculated as the amount of glucose infused (mg x kg-1 x min-1) divided by the mean 
serum insulin level during the last hour of the clamp (120-180 min). The results correspond 
well with the “gold standard” euglycemic clamp technique 111. In addition, the method 
provides a measure of beta-cell function or insulin secretion, which is not obtained through 
the euglycemic clamp technique. First-phase insulin secretion is calculated as the serum 
insulin area under curve during the first ten minutes of the clamp, and second phase as the 
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area under the curve during the last hour of the clamp. A more detailed description of the 
hyperglycemic clamp method is given in Paper III.  
Other methods of assessing insulin sensitivity and beta cell function include modeling 
based on fasting glucose and insulin levels. Although not a planned endpoint, we chose to 
analyze insulin resistance from the homeostasis model assessment (HOMA-IR) in order to 
compare our results with others 113 (HOMA-IR=fasting serum insulin (mIU/ml) x fasting 
plasma glucose (mmol/l)/22.5) 114.  
 
3.2.6 BMD 
BMD was measured in Paper IV using dual X-ray absorptiometry (DEXA) (GE Lunar 
Prodigy, Lunar Corporation, Madison, WI, USA) at the following sites: dual hip, lumbar 
spine and total body. We used the mean of the left and right hip measurements for analyses. 
For participants with metallic implant in one hip, the measurement from the eligible hip was 
used in the analyses. The scanner was calibrated daily against the standard calibration block 
supplied by the manufacturer (aluminium spine phantom), and these measurements showed 
no drift throughout the study. In a quality study of 30 volunteers of different gender and ages, 
and both with and without osteoporosis, BMD scanning was performed twice the same day by 




3.3.1 Vitamin D doses and safety 
At the time of the study planning, most intervention studies on vitamin D had used doses 
ranging from 4-800 IU/d. Based on the considerations outlined in section 1.2, much attention 
was drawn towards the use of higher doses which would be more similar to the natural 
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supplies from UVB-radiation in a traditional outdoor life. Being outdoor with easy clothing a 
sunny summer day will after a short time induce the production of 10-20,000 IU of vitamin D3 
in the skin 115. Conversely, safety studies using graded doses of 0 – 10,000 IU/d given for five 
winter months resulted in serum 25(OH)D changes from -11 nmol/l to +158 nmol/l, and no 
signs of toxicity 116. Based on reviews of vitamin D safety, no harm would be expected with 
doses up to 10,000 IU/d 117,118, or below serum 25(OH)D levels of 374-700 nmol/l 1,117,118. 
Our research group performed a pilot study before starting the intervention studies, where 
seven healthy group members were supplemented with 40,000 IU/w (equaling 5700 IU/d) for 
six months. A slight reduction in serum PTH was seen, and no hypercalcemias or adverse 
events were registered (data not published). This dose was therefore selected for the 
intervention studies, and measurements of serum calcium and creatinine were performed 
throughout the studies for safety monitoring. 
 
3.3.2 Study medication 
In Paper III, the participants with low serum 25(OH)D levels were randomized to receive 
capsules of 20,000 IU vitamin D3 to be taken twice weekly, or identical looking placebo 
capsules. In Paper IV, which was a study among women with reduced BMD, all the 
participants were given a daily supplement of 800 IU vitamin D3 and 1000 mg calcium. This 
is standard treatment for osteoporosis, and also commonly used in the placebo groups in 
clinical trials in this particular patient group 119. In addition, the treatment group was given 
capsules of 20,000 IU vitamin D3 to be taken twice a week. In total this constituted an average 
daily dose of 6500 IU. The placebo group received identical looking placebo capsules.  
In both the intervention studies, the participants received a calendar as an aid to 
remember to take the study medication. In Paper III, phone calls from the study nurse at one 
and three months were used to assure that the study medication was taken as planned. The 
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participants brought the remaining study medication at the final six month’s visit for counting. 
In Paper IV, a study visit every third month was performed, and compliance was checked as 
the participants brought their remaining study medication to be counted at each visit. For the 
participants living far from the hospital, this control was performed by phone from the study 
nurse, and these participants brought all their remaining study medication to be counted at the 
final twelve month’s visit.  
 
3.3.3 Randomization 
The randomization was performed by the central randomization unit at the Clinical Research 
Center, University Hospital of North Norway, using block-randomization with various block-
sizes. In Paper IV, stratification based on current smoking and previous use of 
bisphosphonates was included to ensure an equal distribution of these characteristics between 
the treatment and placebo groups. In both studies, the randomization numbers with treatment 
allocations were provided directly to the hospital pharmacy where the medication boxes were 
prepared and delivered each participant at baseline by the study nurse. In summary, both 
studies were randomized, double blind clinical trials; neither the participants nor the staff 
performing the examinations nor the researchers knew the randomization status of the 
participants during the study.   
 
3.3.4 Follow-up and safety 
The participants in both intervention studies were asked to stop any vitamin D supplements at 
baseline, and in Paper IV, also calcium supplements. Generally, sunbed use was discouraged, 
and persons taking sunbed regularly were not included. Limited sunbed use before special 
occasions was not an exclusion criterion, but the study medication should be temporarily 
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stopped if using sunbed or if going on a sunny holiday. In Paper IV, the basic calcium and 
vitamin D supplements should however be continued.  
Adverse events were asked for and registered through a phone call from the study 
nurse at one and three months, as well as at the final visit at six months in Paper III. In Paper 
IV, adverse events were registered at the visits every third month. Blood for serum calcium, 
ionized calcium, PTH, phosphate and creatinine were sampled and analyzed. This was done at 
the local health center for participants living far from the hospital, and the samples were 
mailed to the University Hospital of North Norway. Thus, all samples were analysed at the 
same laboratory. Exclusion criteria with special relevance to vitamin D were predefined. 
Participants with serum calcium >2.80 mmol/l should be excluded, and participants with 
serum calcium in the range 2.60 – 2.80 mmol/l should be retested and excluded if still above 
2.60 mmol/l.  
 
3.4 Power calculations and statistics 
Statistical methods and power calculations (for the intervention studies) are described in detail 
in Papers I-IV.  
In general, all tests were done two-sided, and a significance level was set at 0.05. 
Normal distribution of the variables was assessed by visual inspection of histograms, and log-
transformation resolved non-normality so that parametric statistical tests could be used. 
Seasonal adjustment is of high importance when examining serum 25(OH)D levels. In Paper I 
and II, such adjustment was done using dummy variables for each month when assessing 
serum 25(OH)D as a continuous variable. To address possible non-linear associations 
between baseline serum 25(OH)D levels and later type 2 diabetes in Paper II, we also 
constructed quartiles of serum 25(OH)D levels within each month before pooling them 
together 120 (closer discussed in section 5.2.3). 
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In Paper I, comparison between the different smoking subgroups were made using Chi 
square tests or analyses of variance (ANOVA) using the Bonferroni correction. General linear 
models were used to compare estimates adjusted for confounders. To assess the effect of 
amount of smoking on serum 25(OH)D levels, the variables number of cigarettes smoked/d, 
years of smoking, and years since smoke cessation were grouped into categories, followed by 
analyses of linear trends using general linear models. When the six different serum 25(OH)D 
methods were compared with regard to smoking, a linear mixed model was used.  
In Paper II, we used the Cox regression model in the main analyses. Smokers and non-
smokers were evaluated separately, and adjustments for number of cigarettes and years of 
smoking were performed in the smokers. In addition, the possible confounders age, sex, BMI, 
and physical activity were included in the final models. To further study the effect 
modification of BMI, we performed analyses stratified by BMI quartiles. There will 
inevitably be some degree of uncertainty regarding the year of diagnosis for the diabetes 
cases. For participants with unknown year of diabetes diagnosis, a year midway in the 
observation time was imputed for the main analyses, and sensitivity analyses with these 
participants excluded were also performed. In addition, we performed logistic regression with 
diagnosis of diabetes (yes or no) as dependent variable to study whether the year of diagnosis 
affected the results.  
 Participants with high and low levels of serum 25(OH)D in Paper III were compared 
with independent t-tests or chi-square tests for continuous or categorical variables, 
respectively. General linear models were used to compare estimates adjusted for possible 
confounders. Also, baseline characteristics of participants randomized to treatment versus 
placebo in Papers III and IV, were compared with independent t-tests or chi-square tests. 
Changes in outcome variables from baseline to final examination in the treatment and placebo 
groups were compared using independent t-tests. In Paper III we also studied the treatment 
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effect by using analysis of covariance (ANCOVA) models with log-transformation of baseline 
and final outcome values; allowing us to adjust for baseline differences and present the 
relative effects of the treatment compared to placebo 121.  
In the two intervention studies, the analyses were performed both as per-protocol and 
intention-to-treat analyses, with the last observation carried forward. 
 
3.5 Ethics 
All the participants provided a written informed consent prior to the examinations. The 
studies were recommended by the Regional Committee for Medical and Health Research 
Ethics, North Norway, and approved by the Norwegian Data Inspectorate. The intervention 
studies were also approved by the Norwegian Medicines Agency, and registered at 
ClinicalTrials.gov (NCT00809744 (Paper III) and NCT00491920 (Paper IV)). 
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4. Summary of results 
 
Paper I 
In this paper, the main finding was an interference between the ECLIA (Roche) assay for 
serum 25(OH)D measurements and smoking. In the 6932 participants included from the 4th 
Tromsø Study where ECLIA was used, smokers had more than 20 nmol/l higher serum 
25(OH)D levels than non-smokers, with former smokers slightly above never smokers (never 
smokers 51±17 nmol/l; former smokers 54±17 nmol/l; and current smokers 72±17 nmol/l, p 
for difference <0.01). A dose-response relationship between smoking and serum 25(OH)D 
levels was evident, with serum 25(OH)D levels increasing with number of cigarettes and 
years smoked in current smokers and decreasing with years since smoking cessation in former 
smokers. In the validation studies where serum 25(OH)D levels were measured in 54 smokers 
and 53 non-smokers, the ECLIA (Roche) method was significantly different from the five 
other methods in finding higher levels in smokers. The results indicate that smoking interferes 
with the serum 25(OH)D measurement in a dose-dependent manner using this particular 
immunoassay. The mechanisms are not known and further exploration is needed.  
 
Paper II 
In this paper, non-smokers (n=4157) and smokers (n=1962) in the 4th Tromsø Study were 
assessed separately due to the interference between smoking and serum 25(OH)D 
measurements discovered in Paper I. In both groups, baseline serum 25(OH)D levels in 1994 
were inversely associated with risk of subsequent diabetes during 11 years of follow-up, so 
that the risk of developing type 2 diabetes was approximately doubled in the lowest versus the 
highest quartile of serum 25(OH)D when adjusting for age and gender. Hazard ratios (HRs) 
(95% CI) were for non-smokers 1.89 (1.25-1.88), and for smokers 2.68 (1.18-6.06). 
 42
Accordingly, each 10 nmol/l increase in serum 25(OH)D led to a 14-15% decreased risk of 
developing type 2 diabetes (HR (95% CI) for non-smokers 0.86 (0.78-0.95) and for smokers 
0.85 (0.74-0.98)) when serum 25(OH)D was assessed as a continuous variable. Further 
adjustment for BMI attenuated the risk estimates in both models so they were no longer 
significant. Thus, BMI-adjusted HRs (95% CI) for lowest vs highest serum 25(OH)D quartile 
were for non-smokers 1.40 (0.91-2.14) and for smokers 1.50 (0.64-3.55). Accordingly, for 
each 10 nmol/l increase in serum 25(OH)D, BMI-adjusted HRs (95% CI) were for non-
smokers 0.95 (0.86-1.05) and for smokers 0.96 (0.83-1.12). However, stratified analyses 
according to quartiles of BMI showed both in smokers and non-smokers still a statistical 
significant decreased risk of developing type 2 diabetes with increasing serum 25(OH)D 
levels in the leanest BMI quartile (BMI <23.2 kg/cm2), with a 38-44% risk reduction per 10 
nmol/l increase in serum 25(OH)D, indicating a possible protective effect of vitamin D 
independent of BMI. As there were low numbers of cases in this quartile, these results must 
be interpreted with caution.    
 
Paper III  
In this paper, we compared measures of glucose and lipid metabolism between otherwise 
healthy adults with low and high serum 25(OH)D levels (40.3±12.8 nmol/l (mean±SD) 
(n=108) and 85.6±13.5 nmol/l (n=54), respectively). Subjects with low levels had 
significantly higher HbA1c (5.55±0.35 versus 5.37±0.36%, p<0.01), and triglyceride (TG) 
levels (geometric mean 1.07 versus 0.89 mmol/l, p=0.03), and lower ISI (geometric mean 
0.13 versus 0.17 µmol x min-1 x kg-1 x pmol-1, p=0.04) than those with high levels. Physical 
activity differed between the two groups, and adjustment for this possible confounding factor 
removed the significant difference between the groups regarding ISI and TG, but not HbA1c. 
However, in a subsequent randomized double-blinded placebo-controlled trial (RCT) in 104 
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participants with low serum 25(OH)D levels, six months supplementation with high dose 
vitamin D3 did not lead to improvements in any of these measures as compared to placebo. 
Although not significant from the placebo group, fasting glucose and HbA1c increased in the 
supplemented group. In the 94 participants completing the study, achieved serum 25(OH)D 
levels were 142.7±25.2 and 42.9±17.3 nmol/l in the treatment and placebo group, 
respectively. Reasons for not completing the study were medical reasons (n=2), consent 
withdrawal (n=1), technical problems (n=3), lost to follow-up (n=3) and death (n=1). 
Numbers of adverse events were similar in the two groups, and no hypercalcemias were 
observed. One participant in the placebo group died of unknown reasons.  
 In spite of confirming previous observational findings of an inverse relationship 
between serum 25(OH)D and measures of metabolic dysregulation in the case-control study, 
the findings from the RCT did not support a causal role of vitamin D in this regard. The 
interpretation of the results might however be limited due to short follow-up time and the dose 
used, as the resultant serum 25(OH)D level was higher in the treated group than in the 
controls at baseline. The ideal serum 25(OH)D level may therefore have been exceeded.  
 
Paper IV  
In this paper, we found that one year treatment with high dose vitamin D3 administrated with 
calcium was not better than standard dose of vitamin D3 in improving or maintaining BMD in 
297 postmenopausal women with reduced BMD. Both treatments led to marginal 
improvements in BMD at the hip, and maintenance of BMD at the femoral neck, spine and 
total body. Serum 25(OH)D increased from 71±23 (mean±SD) to 185±34 and from 71±22 to 
89±17 nmol/l in the high and standard dose vitamin D group, respectively. Although not 
adjusted for multiple comparisons, predefined subgroup analyses indicated a better effect of 
standard dose at certain measurement sites in persons with osteopenia rather than 
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osteoporosis, and with serum PTH levels below the median (4.8 pmol/l). Bone turnover 
markers were reduced in both groups, but the bone formation marker P1NP was more reduced 
in the standard dose group (-10.7±14.2 µg/l in the high dose group, and -14.3±15.4 µg/l in the 
standard dose group, p<0.05). As the reduction in both resorption and formation markers were 
associated with an increase in BMD, this might indicate that the standard dose was the more 
efficient. Twenty-two participants did not complete the study (medical reasons, n=15; consent 
withdrawal, n=8). The results were similar when analyzed per-protocol as intention-to-treat. 
The number of adverse events did not differ significantly between the treatment groups, 
although the number of transient hypercalcemias (as defined by serum calcium >2.60 mmol/l) 
was non-significantly higher in the high dose group (nine versus four). Both baseline serum 
25(OH)D levels and calcium intake were higher than expected from the general population, 
and we cannot exclude that high dose vitamin D would have had another effect in vitamin D 
deficient women. However, as a maintenance treatment in vitamin D replete women with low 




5. General discussion 
 
This thesis combines data from epidemiological observational studies, one methodological 
study and two intervention studies. All these approaches are prone to limitations which might 
affect the validity of the findings. Internal validity refers to whether the findings are true for 
the population studied, while external validity refers to whether the findings also applies to 
populations not studied. Both types of validity are challenged by two categories of errors, 
namely random errors and systematic errors.  
 
5.1 Random errors 
Random errors refer to imprecision in measurement, data processing or calculation, which 
might decrease the precision in the estimates, and reduce reproducibility 122. Although not 
possible to eradicate completely, these are best prevented through a continuous focus on 
quality all the way through the research process. This includes optimizing the study design 
and the inclusion of adequately sized study samples. Further, statistical tools are used to 
minimize the impact of these errors.  
 A statistical type 1 error denominates reporting a difference which is not real. To avoid 
that, strict statistical criteria are predefined to assess when a finding should be regarded 
significant. We have in the papers included in this thesis, set the significance level at 0.05, 
which means that a p<0.05 leads to rejection of the null hypothesis. According to the normal 
distribution, one in 20 non-significant findings will by chance turn out significant. Hence, the 
more statistical comparisons performed, the greater the chance will be for reporting a false 
significant finding. This implies that when multiple comparisons are performed, the results 
must be interpreted carefully 123. 
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In Paper IV, we had predefined certain strata of participants for subgroup analyses; 
namely participants with baseline serum 25(OH)D or PTH below or above the median, age 
below or above 65 years, and with or without osteoporosis in the hip or L2-4. We found 
significant differences in the effects of high dose vitamin D treatment on BMD in participants 
with T-score >-2.5 in L2-4 and in participants with plasma PTH below the median (4.8 
mmol/l), where standard treatment was better at the femoral neck and total hip, respectively. 
The a priori selection of strata reduces the chance of type 1 errors. However, in total 40 
comparisons were made, and the number of significant findings were therefore as expected 
through the statistical distribution. A possible interpretation is therefore that this was nothing 
but random findings without significance. However, the direction of the estimates - although 
not significant - was also the same at the other measurement sites. In addition, the results were 
paralleled by what we found for bone turnover markers, increasing the validity of the 
findings. Nonetheless, this illustrates why such results must be interpreted carefully, and that 
they can be regarded hypothesis-generating rather than evidence of causality.  
 A type 2 error denominates not finding a difference which is real. This might happen if 
the number of participants included in a study is too small or the drop-out rate higher than 
expected. Adequately sized study samples will prevent this kind of error.   
 Paper I and II were based on data from the Tromsø Study, which included large 
number of participants, minimizing the risk of type 2 errors. In Paper I, we also included 53 
non-smokers and 54 smokers in order to study the effect of smoking on the measurement 
methods. This was a pragmatic number based on what is commonly included in that kind of 
studies and what was practically possible. Also – if we could not find a difference between the 
methods with this study size, the effect could probably be regarded of little practical 
importance. However, the effect of smoking was evident, which had implications also for 
Paper II and III (See also section 5.2.1).  In Paper II, the power was thus restricted due to the 
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need of stratifying by current smoking. We found that those in the lowest quartile of serum 
25(OH)D both in smokers and non-smokers, had higher HR of developing type 2 diabetes 
when adjusted for age and sex only. After adjustment for BMI, the estimates were attenuated 
and no longer significant. Still, there was a 40-50% increased risk in the lowest serum 
25(OH)D quartile, with the confidence intervals including 1.0. The number of participants and 
events were very similar to those reported from a Finnish study 67, who reported similar 
findings – an attenuation of estimates and loss of significance after adjustment for BMI. Later, 
the same research group published a new paper where the cohort from the first study was 
extended to include also a second cohort, more than doubling the numbers of participants and 
events. This time, the findings were significant also after adjustment for BMI, however, only 
in men (HR (95% CI) for developing type 2 diabetes 0.28 (0.10-0.81)) 65. This could suggest 
that the power in our study was limited to discover a consistent association independent of 
confounding factors.   
 In Paper III, the study sample size in the RCT was based on power calculations using 
the results from a previous work from our research group 60. In that study, which failed to find 
a difference in ISI between 15 persons with secondary hyperparathyroidism and 15 controls, 
there was a significant difference in ISI between persons with serum 25(OH)D above and 
below the median. This difference was, however, greater than the difference we found in the 
case-control part of Paper III, thus, one could suspect that the present study was 
underpowered. Notably, the study size was similar to two other recently published studies 
which did find an effect on insulin sensitivity of vitamin D supplementation 113,124, and the 
direction of the estimates did not favor vitamin D treatment above placebo in our study. 
Further, the study efficacy was maximized through the strict inclusion criteria to limit 
confounding and control the distribution by age, gender and BMI. Thus, we find it unlikely 
that we should have missed a positive effect of vitamin D treatment on insulin sensitivity due 
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to the study size. The discrepancy regarding results might rather reflect differences in study 
population characteristics or resulting serum 25(OH)D levels, as discussed in section 6.2. 
  The number of participants in Paper IV was also based on power calculations prior to 
the study. These calculations had to be recalculated during the inclusion period owing to 
problems with obtaining the planned number during the available timeframe, as described 
more closely in Paper IV. The study was not powered to detect differences in the subgroup 
analyses, underscoring the need of interpreting those results carefully.  
 For both the intervention studies, the rates of non-completion were low. This increases 
the internal validity of the findings.  
 
5.2 Systematic errors 
Systematic errors, which might result in incorrect estimates and thereby reduce the validity of 
the findings, can be discussed in terms of selection bias, information bias, and confounding.  
 
5.2.1 Selection bias 
Selection bias is present when individuals have different probability of being included in the 
study sample according to the exposure or the outcome 125.  
In Paper I and II, data was based on participants in the 4th Tromsø Study. This was a 
large study including both men and women in a wide age range. Volunteers in population-
based studies have been reported to be more interested in health issues; hence they could 
represent a healthier population compared to non-participants. High attendance rates, 
approximating nearly 80% in both visits of the Tromsø Study, reduce the risk of selection bias 
and increase the external validity. However, the attendance rate was lower in the youngest and 
oldest age groups, as only 52% and 54% of the invited among 25-34 years and 75-84 years 
old subjects, respectively, attended the second phase of the study 126. Serum 25(OH)D tends to 
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decrease with age, while incidence of type 2 diabetes increases. This could therefore introduce 
a selection bias towards nil, underestimating the association between serum 25(OH)D and 
subsequent type 2 diabetes. This is, however, speculative, and previous reports from the 
Tromsø Study did not find any significant differences regarding self-reported health between 
participants who only attended the first visit and participants attending both the first and 
second visits 126.  
The inclusion of participants in Paper III was restricted to non-smokers only, as we at 
that time had not yet concluded the analyses in Paper I. Thus, we can not tell whether the 
results also apply to smokers. Smoking increases the risk of diabetes 38, but if there is an 
interaction between smoking and serum 25(OH)D level and insulin sensitivity, is not known.  
   
5.2.2 Information bias 
Information bias results from a systematic tendency for individuals selected for inclusion in 
the study to be erroneously placed in different exposure/outcome categories, thus leading to 
misclassification 125. This misclassification can be differential or non-differential, depending 
on whether the degree of misclassification of exposure is dependent on the outcome or not. 
While non-differential misclassification tends to weaken true associations, the direction of the 
bias when differential misclassification occurs is difficult to predict 125.  
There are many sources of information bias, and one of them relevant to these studies 
is recall bias regarding self-reporting on exposure or confounding variables of life-style like 
smoking, physical activity, sun seeking behavior and food and supplementation use. In Paper 
I, the main exposure variable was smoking habits. It is well known that under-reporting of 
smoking might occur, and also, a tendency to round to nearest five or ten when answering 
questions on amount of smoking has been shown 127. This is clearly illustrated in Fig. 2 and 3, 
where we see self-reported years of smoking and number of cigarettes smoked in the 
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population included in Papers I and II. This influences precision when these variables are used 
in the analyses, and is one important reason for stratifying smokers and non-smokers in Paper 
II where there was such a clear dose-response relationship between amount of smoking and 
serum 25(OH)D levels using the ECLIA (Roche) method.  
Smoking status was extremely important in the validation part of Paper I, where 54 
smokers and 53 non-smokers were included based on self-reporting in the 6th Tromsø Study 
questionnaire. In order to increase study efficacy, we chose to include smokers who reported 
to smoke on average at least five cigarettes daily, and we also wanted non-smokers to have 
been without smoking during the last five years before inclusion. These data were rechecked 
through a new questionnaire at examination. We therefore consider it unlikely that 
misclassification of smoking status has occurred.  
 
 
Fig. 2 Self-reported years of smoking in 4773 former or current smokers in the 4th Tromsø Study. 
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Fig. 3 Self-reported number of cigarettes smoked in 4713 former or current smokers in the 4th Tromsø Study. 
Participants smoking more than 40 cigarettes/d (n=26) were excluded in order to increase readability. 
 
Other life-style related exposures prone to information bias are self-reported physical activity 
and food intake. Validated data on self-reported physical activity was used in all four papers, 
assessed from the questionnaire used in the 4th (Papers I and II) 128 and 6th 129 surveys in the 
Tromsø Study (Paper III), and an international validated questionnaire tool (IPAQ) 109 in 
Paper IV. The correlation between self-reported physical activity and objective measures of 
physical activity or fitness was reported to be from low to moderate, with correlation 
coefficients in the range of 0.11-0.46 109,128,129.  
The correlation coefficient between self-reported intake of different nutrients in the 
food-frequency questionnaire and weighed records, was reported to be better (0.44-0.66), 
however, vitamin D intake from the food-frequency questionnaire was overestimated as 
compared to weighed records, and less than half of the participants were correctly placed in 
quartiles of vitamin D and calcium intake based on self-reports 108. These limitations in self-
reports should therefore be kept in mind. However, as the participants in the Tromsø Study 
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filled out their questionnaires when entering the 4th Tromsø Study, not knowing their serum 
25(OH)D level or later diabetes status, any misclassification would be expected to be non-
differential, diluting the findings.  
The diabetes registry used in Paper II was based on journal screening of participants 
who reported to have diabetes in the questionnaire in the 4th, 5th or 6th Tromsø Study or had a 
HbA1c >6.5% at any of the surveys. In addition, the participant list was linked to diabetes-
related discharge diagnosis in the digital patient records at the University Hospital of North 
Norway. Since the hospital provides the only laboratory in the municipality, the diabetes 
registration committee also had HbA1c measurements taken by the general practitioners 
available when validating the possible cases. Still, some cases might have been missed due to 
the limitation of the registry to include only hospital based journals. We expect that to be a 
non-differential misclassification, diluting the observed associations. One could however 
speculate that since lower serum 25(OH)D levels are associated with a number of diseases, 
the risk of getting in touch with health services and having a measurement of serum glucose 
or HbA1c would be greater in those with low serum 25(OH)D levels, increasing their chance 
of having a type 2 diabetes detected. If so, this would be a differential misclassification, 
which might have led to a bias away from nil, resulting in falsely elevated HRs. However, we 
anticipate the magnitude of such a misclassification to be low.   
Also, the data could include persons already having diabetes without knowing it at 
baseline in the 4th Tromsø Study 1994-95, and these persons could in theory have lower serum 
25(OH)D levels owing to deteriorated health and less outdoor time. The time lag in 
diagnosing the diabetes would then give the false impression that low serum 25(OH)D levels 
were evident before the diabetes was established, introducing a bias away from nil. This 
phenomenon is also called reversed causation. In addition to excluding participants with self-
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reported or registered diabetes at baseline, we therefore also excluded everyone with a 
baseline serum HbA1c >6.5%, regardless of later diabetes diagnosis.    
In Paper III, we chose to invite participants in the 5-10 and 80-95 percentiles of serum 
25(OH)D measured in the 6th Tromsø Study. Since there was considerable time span between 
the participation in the 6th Tromsø Study and the inclusion in the present study (median 13 
months), low or high serum 25(OH)D levels were confirmed at screening before inclusion, 
using the same laboratory method (ECLIA, Roche) as in the 6th Tromsø Study. As this 
method later was withdrawn, we chose to measure baseline and six months serum 25(OH)D 
with LC-MS/MS, both done in frozen samples. This resulted in a change in vitamin D status 
so that one participant with low serum 25(OH)D in the 6th Tromsø Study and at screening was 
classified as a case when actually having a high serum 25(OH)D level at baseline. As the 
participant had consistently low serum 25(OH)D levels during considerable time before 
inclusion, the impact of an increase during the last weeks before the clamp would probably be 
of minor importance. It has been reported that an effect of vitamin D supplementation on 
insulin sensitivity needs more than three months to be evident 113, and exclusion of this 
participant did not change the results. 
 
5.2.3 Confounding  
The term confounding refers to when a non-causal association between a given exposure and 
an outcome is observed as a result of a third variable associated with both the exposure and 
the outcome 125. Confounding is more likely to occur in observational than in experimental 
epidemiology. By the means of random allocation, the subsamples of the study population are 
expected to be comparable with regard to the distribution of both known and unknown 
confounders. In observational studies, multivariate analyses and stratification are the analytic 
tools that are used to control for confounding effects and to assess effect modification 125. 
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 Thus, in Paper I, the results from the 4th Tromsø study, showing that smokers had 
higher levels of serum 25(OH)D than non-smokers, could have been a result of confounding 
factors like differences in BMI, dietary habits, use of supplementation or outdoor time. This 
was adjusted for, and the results remained very similar. In theory, the differences could still 
be a result of residual confounding, although the magnitude of the differences in serum 
25(OH)D levels between smokers and non-smokers made this unlikely. However, the results 
were confirmed in the validation study, with the comparison with five other methods clearly 
showing that the difference found was restricted to the particular assay used in the Tromsø 
Study.  
 The seasonal variation in serum 25(OH)D levels offers an extra challenge regarding 
adjustment in observational studies. This is solved in different ways, from adjusting for 
season dichotomized in summer and winter, to splitting the year in three, four, six, or in each 
month. A simulated model has shown that stratifying participants for instance in quartiles 
based on serum 25(OH)D levels, and thereafter adjusting for season in one way or another, 
might result in a bias away from nil 120. The authors suggested stratification within each 
month, with subsequent pooling of strata. This seems logic, as a person with serum 25(OH)D 
level of 60 nmol/l might be in the upper quartile in January, but in one of the lower in August. 
Accordingly, this method was chosen in Paper II.  
 Confounding by other factors is a more challenging issue in Paper II and in the case-
control part of Paper III. The increased HRs of developing type 2 diabetes observed in the 
participants in the lowest serum 25(OH)D quartile after adjustment for the near obligatory 
confounders age and sex, were attenuated and turned non-significant after adjustment for 
BMI. There is a clear inverse association between serum 25(OH)D levels and BMI 12, which 
is believed to be due to storage and sequestration of vitamin D in fat tissue 11, although 
increased clearance resulting from the proinflammatory state associated with obesity might 
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also contribute 2. However, obesity has also been suggested to result from vitamin D 
deficiency 130, and in that case, BMI would be an intermediate step between serum 25(OH)D 
and type 2 diabetes, and not a confounder. If so, it should not be adjusted for. Intervention 
studies have not supported this hypothesis 131,132, supporting the need of adjusting for BMI. 
As discussed in section 5.1, the lack of significance after this adjustment could also be the 
result of lack of power. When analyses were performed stratified by BMI quartiles, we still 
found an inverse association between serum 25(OH)D and risk of developing type 2 diabetes 
in the leanest group, indicating that differences in BMI could not fully explain the higher risk 
of type 2 diabetes with lower serum 25(OH)D levels observed in the main analyses. 
Importantly, it has been argued that adjustment for BMI is less appropriate than adjustment 
for fat mass as obtained by DEXA or computer tomography (CT) 62. These measures were 
however not available to us.  
 In the case-control part of Paper III, participants with low serum 25(OH)D levels had 
lower ISI and higher TG and HbA1c levels than the participants with high serum 25(OH)D 
levels. To avoid confounding by age, sex and BMI, the inclusion procedure included 
balancing the two groups in regard of these variables. However, there was other differences 
between the groups that could both be associated with serum 25(OH)D levels and the 
outcomes, such as physical activity, fat fish intake and supplementation use. Thus, after 
adjusting for physical activity, the two groups did not differ in TG and ISI anymore; however, 
the difference in HbA1c was still significant.  
 Although a number of variables fulfil the criteria of being a confounder, one caveat is 
that if we could fully adjust for all exposure variables that affected serum 25(OH)D levels, the 
remaining difference between cases and controls would in theory approach nil and only 
represent the genetic variations in serum 25(OH)D levels. Thus, the chance of finding a 
difference would be markedly reduced, and it is therefore not evident that such adjustment 
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should be performed. Nonetheless, as we found no effect of supplementation with vitamin D3 
as compared to placebo, a causal relationship was not established.  
 
5.3 External validity 
The generalisability of the study findings depends on whether the source population is 
representative also of other populations. The population of Tromsø is regarded not 
substantially different from the Norwegian population with respect to age and sex distribution 
133. However, the geographic location at 69ºN will impact the amount and variation of UVB 
exposure 5. As long as we have used the biomarker 25(OH)D, which includes both vitamin D 
intake and UVB mediated production, the associations between measured serum levels and 
health outcomes should not be influenced by that. In contrast, studies including only vitamin 
D intake, might be less valid as they do not take into account UVB exposure.  
   The recruitment procedure to the BMD study might have favored participants with 
especially high health interest and behavior. This is supported by the observation that the 
intake of calcium and vitamin D was higher than expected from the general Norwegian 
population 134. Accordingly, baseline serum 25(OH)D was also substantially higher (71 ± 23 
nmol/l) than the levels found in 1712 never smoking women between 50 and 80 years in the 
4th Tromsø Study, where serum 25(OH)D was 50 ± 16 nmol/l (data not published).  We can 
therefore not rule out that the results would have been different in a more vitamin D-deplete 
population.  
 In the clamp study, recruitment was based on serum 25(OH)D levels only, and persons 
with impaired glucose tolerance or diabetes mellitus were excluded. As such, the study can be 
regarded as an attempt of defining the role of vitamin D deficiency for glucose metabolism in 
the general population. Inclusion of at risk participants might therefore have yielded other 
results, as shown by others 113,124. Although our study was not powered for subgroup analyses, 
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the directions of the estimates gave no indication of different results in the subgroups of high 
BMI or high HOMA-IR – both regarded as indices of insulin resistance. The inconsistency in 
results between these studies may therefore also have other explanations, like ethnicity. 
It is a common problem of RCTs that the characteristics of the population included not 
necessarily reflect the characteristics of the population at risk seen in the real world, limiting 
the external validity of the findings 135. Both Paper III and IV had strict exclusion criteria, 
both for safety reasons and for avoiding interference with the results from comorbidity that 
might have affected the outcome. This means that the results not necessarily can be applied to 
more heterogeneous populations. This is most relevant for Paper IV, as Paper III must be 
regarded an experimental study of healthy participants.  
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6. Implications and further research 
 
6.1 Smoking and 25(OH)D assays  
We have shown that smoking might interfere with serum 25(OH)D measurements, a finding 
that as far as we are concerned, has not previously been reported. According to the producer, 
this method was widely used in clinical practice in several countries, where overestimation of 
serum 25(OH)D levels in smokers must have occurred.  This is concerning, since smokers 
also have increased risk of osteoporotic fractures 37, thus, diagnosis and treatment of vitamin 
D insufficiency would be of specific importance. In addition, studies reporting use of this 
assay should be interpreted carefully, as misclassification regarding vitamin D status in 
smokers is likely to occur. The method is now withdrawn.  
 We do not know the exact mechanism(s) for this interference, and this would also be 
very challenging to explore as there are more than 4000 substances present in cigarette smoke 
136. Until the mechanisms are clarified we can therefore not rule out that such interference also 
might affect other types of analyses and assays. We therefore suggest particular attention to be 
paid to this problem when analyses are being developed and validated. 
 
6.2 Vitamin D, metabolic disturbances and type 2 diabetes 
Consistent with other observational studies 54-64,137,138, we have observed that vitamin D 
insufficient persons have lower insulin sensitivity and higher HbA1c than vitamin D sufficient 
controls. In accordance with others 65-67, we have also demonstrated an inverse association 
between serum 25(OH)D concentrations and the risk of developing type 2 diabetes, which to a 
large extent seems to be mediated through differences in BMI.  
However, associations found in observational studies can not be interpreted as 
evidence of causality, and there is inconsistency in the literature as there are several studies 
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which do not report such relations 139,140. In contrast, an effect on the metabolic parameters in 
RCTs using vitamin D supplementation, would strongly support a causal role of vitamin D 
insufficiency in metabolic disturbances. Notably, we found no beneficial effect of 
supplementation on these endpoints in the intervention trial, which makes a causal relation 
between vitamin D insufficiency and diabetes less likely.  
The results of the intervention study are consistent with other recently published 
studies. Using low vitamin D doses, and in combination with calcium, no effect on diabetes 
during seven years of follow-up was observed in more than 33,000 women in the Women’s 
Health Initiative as compared to placebo (HR (95% CI) 1.01 (0.94-1.10)) 141. Likewise, in the 
RECORD trial, there was no effect of vitamin D supplementation with or without calcium on 
development of diabetes in more than 5000 older persons during a follow-up period of 2.5 
years (odds ratio (OR) (95% CI) in intention-to-treat analyses: 1.11 (0.77-1.62), and in per-
protocol analyses: 0.68 (0.40-1.16)) 142. The results of these two studies, which originally 
were designed for skeletal purposes, have been questioned as vitamin D doses used and 
compliance may have been too low. However, also studies using high dose treatment (40,000 
IU/w, or 100,000 or 200,000 IU as one single dose) have failed to improve glycemic control 
in 36 and 61 already diabetic patients 143,144, and similarly did 100,000 IU given twice not 
improve insulin sensitivity or fasting glucose in vitamin D insufficient persons without 
diabetes 145. The last study was small (n=33), had no control group, and was limited by short 
duration (four weeks). 
As there has been considerable interest in vitamin D insufficiency as an explanation 
for the increasing prevalence of type 2 diabetes, our results are therefore important, indicating 
that there is no need for changing the recommendations of vitamin D intake in the general 
population. However, there is still a need for more studies including participants with both 
high risk of diabetes and established vitamin D insufficiency. Adequately powered long-term 
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studies with diabetes as an endpoint should be performed before drawing a final conclusion. 
We cannot preclude that the serum 25(OH)D level achieved in the intervention study was 
above the ideal level for glucose metabolism, assuming an U-shaped relation between glucose 
dysregulation and serum 25(OH)D levels. Although speculative, such an association has 
recently been suggested by others 140, and has also been observed in relation to frailty 146, 
some types of cancer 147, and mortality 148. Finally, the results may be different in other 
populations, as significant effects of supplementation on insulin sensitivity recently have been 
reported in South-Asians in particular 113,124.  
Serum lipid levels are associated with both insulin resistance and cardiovascular 
disease 149. Consistent with reports from other studies, we found lower TG levels in 
participants with high serum 25(OH)D levels 64,137,138. However, supplementation with high 
dose vitamin D3 to those with low serum 25(OH)D levels did not affect the TG levels, or any 
other lipid measurements. This is in accordance with most other intervention studies 
113,124,144,150-152, although one study found a concomitant reduction in TG levels and an 
increase in low density lipoprotein levels after one year of daily supplementation with 3332 
IU vitamin D3 
132. A limitation with these studies, including ours, is that the participants were 
not included based on presence of hyperlipidemia or hypertriglyceridemia; thus, RCTs using 
vitamin D in participants with such traits should be performed.  
 
6.3 Vitamin D and BMD 
Our results suggest that high and standard dose vitamin D are equally efficient in improving 
or maintaining BMD in mainly vitamin D-replete postmenopausal women with reduced 
BMD, and that bone turnover markers were more reduced using standard dose, indicating that 
this dose was the most effective. To be interpreted with care, the subgroup analyses indicating 
better effect of standard dose on BMD in those with higher baseline BMD and lower PTH, 
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should prompt alertness when using high dose vitamin D for any purpose. Again, the results 
add support to the current guidelines where a daily intake of 800 IU vitamin D is 
recommended to persons with osteoporosis 83. 
 One important limitation of the study is the use of the intermediate endpoint BMD 
instead of the clinical relevant endpoint fracture. BMD has been shown to predict fracture 
with the same strength as hypertension predicts stroke, and better than serum cholesterol 
predicts coronary heart disease 153, but still, BMD forms only one component of bone strength 
and fracture risk. Recently, the use of BMD as an intermediate endpoint in calcium studies 
(with or without vitamin D) was questioned 154. Vitamin D has been shown to reduce risk of 
falling 155, which might represent another mechanism for fracture reduction not reflected by 
BMD changes.  
  Several authors argue that a serum 25(OH)D level >50 nmol/l is sufficient for bone 
health 71,83. It is therefore interesting that even with a higher than expected baseline level of 70 
nmol/l, and with an already sufficient calcium intake, serum PTH decreased substantially in 
both groups, bone turnover was reduced, and BMD was maintained or slightly increased. This 
might indicate that a serum level of at least 90 nmol/l (as achieved in the standard dose group) 
is more beneficial than lower levels. However, consistent with other studies of vitamin D3 and 
calcium supplementation 97,98,156-158, the BMD gain was small, and the clinical importance 
uncertain. Similarly, our research group found no differences between high dose vitamin D3 
(40,000 IU/w), intermediate dose (20,000 IU/w) or placebo regarding BMD or bone turnover 
markers when given to 312 overweight or obese participants coadministrated with calcium 
500 mg/d, and the changes in BMD after 12 months were only marginal 159. Another study 
including 71 patients with multiple sclerosis, reported no difference in bone loss in those 
given 20,000 IU/w vitamin D3 and 500 mg/d calcium versus calcium alone for 96 weeks 
160. 
In contrast, in 45 nursing home residents with a baseline serum 25(OH)D of 28.5 ± 10.8 
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nmol/l, BMD at the hip increased 23% after one year supplementation with cholecalciferol 
5000 IU/d, resulting in a serum 25(OH)D of 125.6 ± 38.8 nmol/l 161. This impressive increase 
might have been due to mineralization of osteoid caused by osteomalacia.  
It could be argued that the duration of our study (one year) was too short for finding an 
effect on BMD. However, when bone turnover is reduced by vitamin D treatment, the 
secondary mineralization, which usually takes about six months to complete, will improve, by 
which the proportion of bone with high mineral content increases. This effect will for the 
greatest part be seen during the first year of therapy 71. Accordingly, in the Amsterdam 
Vitamin D Study, where 400 IU vitamin D3 or placebo was given to 348 women >70 years, 
BMD in the femoral neck increased 1.9% in the first study year and only additional 0.2% the 
next year 158. Also, a positive effect on lumbar spine BMD in 240 Danish women treated with 
1000 mg calcium and 560 IU vitamin D/d versus placebo for two years was mainly seen 
during the first year 156. Inclusion in our study of a substantial proportion of participants 
already using vitamin D and calcium supplementation might therefore have diluted an effect. 
We found similar results when these subjects were excluded, although the study was not 
powered for such subgroup analyses.  
Consistent with previous meta-analyses 102,103, two recently published meta-analyses 
162,163 found no fracture reduction whatever vitamin D dose used when given alone (RR (95% 
CI) 1.01 (0.92-1.12)) 163, while there was a modest fracture reduction of vitamin D 
irrespective of dose when given together with calcium (RR (95% CI) 0.92 (0.86-0.99)) 163. 
Both meta-analyses underscored the need for intervention trials using high doses. Our study, 
combined with the results from a recently published Australian study showing an increase in 
fracture rates in participants randomized to an annual dose of 500,000 IU cholecalciferol for 
3-5 years as compared to placebo 164, do not support the use of high doses in populations with 
increased risk of osteoporotic fractures, neither alone nor with calcium. 
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Interestingly, VDR polymorphisms might modify the effect of vitamin D 
supplementation on BMD 165. As materials for genetic analyses were collected in both 
intervention studies, this can be studied more closely in the future. 
 
6.4 Vitamin D doses, achieved serum 25(OH)D levels, and safety 
In the two intervention trials, there were similar numbers of adverse events in both the 
treatment and the placebo groups. Although not statistically significant, there were more 
hypercalcemias in the high than in the standard dose group in the BMD study, while no 
hypercalcemias were observed after six months in the clamp study. This most likely reflects 
the impact of concomitant calcium supplementation, and not so much achieved serum 
25(OH)D levels, as there was such cases both in the standard dose group (achieved serum 
25(OH)D level 89 nmol/l), and the high dose group (achieved level 185 nmol/l) in the BMD 
study, but not in the treatment group in the clamp study (achieved level 142 nmol/l). Also, 
hypercalcemias in the BMD study occurred at a wide range of serum 25(OH)D 
concentrations, as shown in Table 3.  
The ionized calcium concentration, which shows free calcium regardless of the 
amount of binding protein, was also measured in the BMD study, and after an initial increase, 
the levels stabilized with no statistically significant differences between the standard and high 
dose groups (Fig. 4).  
Other complications related to vitamin D toxicity results from longstanding 
hypercalciuria or hypercalcemia, leading to kidney stones or vascular and soft tissue 
calcifications 166. One participant in the high dose group in the BMD study experienced back 
pain and hematuria during an angiography with a percutaneous cardiac intervention 
procedure, and although no calcifications were seen on a CT taken thereafter, the diagnosis 
can not be excluded. There was one case of unstable angina pectoris in the standard dose 
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group, and two cases of transient ischemic attack in the high dose group in the BMD study, 
both occurring early (after two and five months in the trial, measured serum 25(OH)D were 
then 146 and 150 nmol/l, respectively, serum calcium in normal range). We find it unlikely 
that these events should be related to the study medication, however, concern has recently 
been raised towards a possible increased risk of cardiovascular morbidity when using calcium 




Fig. 4 Serum ionized calcium levels at baseline, 3, 6, 9 and 12 months in 149 participants receiving high dose 
vitamin D3 (6500 IU/d) and 148 participants receiving standard dose (800 IU/d). There were no significant 
differences in serum ionized calcium levels between the groups at any time point.
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Table 3 Characteristics at screening and at event of participants with serum calcium >2.59 mmol/l during the study.  
 











































25.4 2.34 3.5 61 HD 3 2.77 . 1.3 188 2.39 E 
66 26.2 2.29 3.7 59 HD 3 2.63 1.31 2.5 144 2.56 C 
56 24.8 2.45 6.2 45 HD 3 2.61 1.33 2.9 178 2.45 C 
60 30.1 2.25 5.6 92 HD 6 2.72 1.34 2.9 203 2.46 C 
55 21.8 2.20 3.5 64 SD 6 2.65 1.34 1.3 101 2.51 C 
65 22.5 2.43 6.2 82 HD 6 2.63 1.36 3.3 190 2.54 C 
69 26.4 2.45 . 50 SD 6 2.62 1.38 3.0 88 2.45 C 
67 27.4 2.35 8.5 37 SD 6 2.62 1.39 3.7 64 2.40 C 
68 28.6 2.44 8.3 35 HD 6 2.60 . 6.3 137 2.42 C 
57 23.9 2.45 4.4 48 HD 12 2.63 1.33 3.7 175 . F 
67 28.5 2.31 10.2 26 SD 12 2.62 1.40 3.9 91 2.57 F 
61 29.2 2.49 4.0 107 HD 12 2.62 1.34 2.8 256 2.39 F 
66 32.5 2.45 2.9 52 HD 12 2.61 1.31 1.9 204 2.28 F 
HD; high dose, SD; standard dose, E; excluded, C; continued in study, F; finished the study.
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 Further, the doses of vitamin D3 used in the intervention trials were substantially 
higher than those used in most clinical settings. The same dose (40,000 IU/w) and an 
intermediate dose (20,000 IU/w) have been used in a one year study of overweight and obese 
participants 131. When comparing the participants receiving vitamin D3 in the three studies as 
shown in Table 4, we find an increase in serum 25(OH)D of 0.55-0.90 nmol/l for each 
microgram vitamin D3 given. This is quite similar to previous reports 
116,168, which also have 
shown that the increase in serum 25(OH)D level will be higher in those starting out low, and 
lower in those starting out high 168. Therefore, it might seem surprising that the increase in 
serum 25(OH)D per given microgram vitamin D3 was exactly the same in the vitamin D 
replete participants in the BMD study as in the vitamin D deplete participants in the clamp 
study. This might be explained by a higher BMI in the clamp study, as higher doses will be 
needed to achieve the same serum 25(OH)D levels in obese than in non-obese subjects 12. 
This is consistent with the lower increase in the overweight study in spite of starting out with 
intermediate serum 25(OH)D levels (Table 4). Of importance is probably also the addition of 
calcium supplementation in the BMD study, as calcium is believed to have a vitamin D 
sparing effect (and vice versa). Thus, higher 1,25(OH)2D resulting from higher serum PTH in 
response to low calcium, increases 25(OH)D turnover and vice versa 71.  
As seen from the SDs of achieved serum 25(OH)D level in Fig. 5, the variation was 
large even if the same dose was given. This is also observed by others 168. It might very well 
be that a more relevant approach in future intervention studies using vitamin D would be to 
define the serum 25(OH)D targets to be achieved rather than the vitamin D doses to be used. 
This would of course be more costly and time-consuming, as consecutively serum 25(OH)D 
measurements followed by individual dose-adjustments would be necessary. Also, the need 
for standardized and precise serum 25(OH)D analyses is obvious. However, if the objective is 
to answer the still unsettled question what the ideal serum 25(OH)D level for multiple health 
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outcomes is, we find that to be the most appropriate approach. Reasonable serum 25(OH)D 
targets in such studies, based on own and others’ findings, would be for instance 50-60 






Fig. 5 Serum 25(OH)D (mean and SD) at baseline, 3, 6, 9 and 12 months in 149 participants receiving high dose 
cholecalciferol (6500 IU/d) and 148 participants receiving standard dose (800 IU/d). There was a significant 










Table 4 Some characteristics of participants receiving high dose vitamin D3  
 
  





Overweight study 131_ 
 
 High dose Standard 
dose 
 High dose Medium dose 
__________________________________________________________________________ 
      
N 
 




12 12 6 12 12 
Average daily vitamin 










1000 mg 1000 mg 0 500 mg 500 mg 
BMI (kg/cm2) 
 
24.9 ± 3.4 24.6 ± 3.3 27.2 ± 3.1 34.6 ± 3.9 34.1 ± 3.6 
Age (years) 
 
62.8 ± 7.8 63.4 ± 6.9 51.5 ± 8.8 47.7 ± 11.1 48.8 ± 11.8 
Proportion women (%) 
 




71 ± 23a 71 ± 22a 42 ± 14a 61 ± 21b 58 ± 22b 
Final serum 25(OH)D 
(nmol/l) 
 
186 ± 34a 89 ± 17a 143 ± 25a 140 ± 35b 101 ± 21b 
Baseline PTH (pmol/l) 
 
5.0 ± 1.6  5.1 ± 1.7 6.1 ± 1.4 5.1 ± 1.6 5.5 ± 1.8 
Final PTH (pmol/l) 
 
3.8 ± 1.1 4.5 ± 1.5 5.1 ± 1.3 4.2 ± 1.5 4.7 ± 1.7 





2.36 ±0.07 2.26 ± 0.07  2.30 ± 0.11 2.32 ± 0.11 







2.26 ± 0.07 2.30 ±0.08 2.30 ± 0.07 




0.71 0.90 0.71 0.55 0.60 
 
a measured by LC-MS/MS, b measured by RIA (DiaSorin), cfinal serum 25(OH)D level minus baseline level  
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A recently released report from Institute of Medicine in the US, has concluded that there are 
no yet proven benefits of achieving a certain amount of vitamin D except for bone health. 
Importantly, based on several reports on U-shaped associations between serum 25(OH)D 
levels and adverse health outcomes, they concluded that higher serum levels than 125 nmol/l 
should be avoided 166. This is in contrast to previous safety reviews, where levels have been 
assumed to be safe up to 375-750 nmol/l 2,117,118,169,170. Interestingly, the report also suggests 
an upper limit of 4000 IU/d, implying that this dose, although not generally recommended, 
can be considered to be safe for anyone. From Table 4 we must assume that such a dose 
would inevitable lead to serum 25(OH)D levels >125 nmol/l in several of the participants. 
Nonetheless, taken together, and with the limitations discussed in the previous chapters, our 
results do not give any support for raising the serum 25(OH)D levels higher than 90 nmol/l. 
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7. Concluding remarks  
 
The results presented in this thesis illustrate that there are still important methodological 
challenges in the assessment of a person’s vitamin D status. Extensive work for international 
standardization of 25(OH)D measurements is ongoing, and will hopefully improve the basis 
of decision-making regarding recommendations of vitamin D intake in the population. 
Although a huge number of observational studies, including ours, report associations between 
higher serum 25(OH)D levels and beneficial health outcomes, these studies do not provide 
sufficient evidence for increasing the intake. Our results from the intervention trials do not 
challenge the current recommendations regarding vitamin D intake or levels in the general 
population or in persons with increased risk of osteoporotic fractures. Further carefully 
designed intervention studies, preferably using serum 25(OH)D targets, are however needed 











The following erratum has been published (Eur J Endocrinol 2010;163:965): 
 
The authors and the journal apologise for errors in the Introduction section of this paper 
published in the European Journal of Endocrinology 2010 vol 163 pp 339–348. Lines 11–14 
of the Introduction section should read as follows: “This reflects the amount of vitamin D 
ingested from food (ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3 )) and the 
amount of vitamin D produced in the skin during ultraviolet B (UVB) exposure (vitamin 
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c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 






3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe) ....................... c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer) .............................. c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose) .................................. c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som du har søkt hjelp for) ....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  









Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis JA; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom fastlege/allmennlege/psykiater) ........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) ..... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 Konfidensielt
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .................. c c
Ved annen sykehuspoliklinikk ........ c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose) ............................................ c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept ............... c c c c
Smertestillende 
reseptfrie ............... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
Ved fRAMMØte vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste  
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe) ...... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose)  ................ c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Demens .......................................................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
c Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon




c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  















yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året































45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Kalktabletter ............................................................ c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 er du gravid nå?
c Ja c Nei c Usikker
Ved fRAMMØte vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)










Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt (ikke kvernet) ................ c c c c c
Kvernet kjøtt  
(pølser, hamburger o.l) ........... c c c c c
Grønnsaker, frukt, bær .. c c c c c
Mager fisk ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks, ørret, makrell, sild, kveite,uer)
KOSTHOLD SPØRSMÅL TIL KVINNER
Appendix C 
International Physical Activity Questionnaires (IPAQ) 
 
 
INTERNATIONAL PHYSICAL ACTIVITY  
QUESTIONNAIRES  
This is the final SHORT LAST 7 DAYS SELF-ADMINISTERED version of IPAQ from the 2000/01 Reliability and Validity Study.  Completed May 2001.  
 
IPAQ: SHORT LAST 7 DAYS SELF-ADMINISTERED 
FORMAT  
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS  
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. Long 
(5 activity domains asked independently) and short (4 generic items) versions for use by either 
telephone or self-administered methods are available. The purpose of the questionnaires is to 
provide common instruments that can be used to obtain internationally comparable data on health-
related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 1998 
and was followed by extensive reliability and validity testing undertaken in 12 countries (14 sites) 
across 6 continents during 2000.  The final results suggest that these measures have acceptable 
measurement properties for use in many settings and in different languages. IPAQ is suitable for 
use in regional, national and international monitoring and surveillance systems and for use in 
research projects and public health program planning and evaluation. International collaboration on 
IPAQ is on-going and an international prevalence study is under development. 
 
Using IPAQ  
Worldwide use of the IPAQ instruments for monitoring and research purposes is encouraged.  
It is strongly recommended, to ensure data quality and comparability and to facilitate the 
development of an international database on health-related physical activity, that 
• no changes be made to the order or wording of the questions as this will affect the 
psychometric properties of the instruments,  
• if additional questions on physical activity are needed they should follow the IPAQ items,  
• translations are undertaken using the prescribed back translation methods (see website)  
• new translated versions of IPAQ be made available to others via the web site to avoid 
duplication of effort and different versions in the same language, 
• a copy of IPAQ data from representative samples at national, state or regional level be 
provided to the IPAQ data storage center for future collaborative use (with permission) by 
those who contribute. 
 
More Information 
Two scientific publications presenting the methods and the pooled results from the IPAQ reliability 
and validity study are due out in 2002. 
More detailed information on the IPAQ process, the research methods used in the development of 
the IPAQ instruments, the use of IPAQ, the published papers and abstracts and the on-going 
international collaboration is available on the IPAQ web-site. 
www.ipaq.ki.se 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
IPAQ: SHORT LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS 
 
 
NOTE: EXAMPLES OF ACTIVITIES MAY BE REPLACED BY CULTURALLY RELEVANT 
EXAMPLES WITH THE SAME METS VALUES (SEE AINSWORTH ET AL., 2000). 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives. This is part of a large study being conducted 
in many countries around the world. Your answers will help us to understand 
how active we are compared with people in other countries. 
 
The questions are about the time you spent being physically active in the last 7 
days.  They include questions about activities you do at work, as part of your 
house and yard work, to get from place to place, and in your spare time for 
recreation, exercise or sport. 
 
Your answers are important. 
 
Please answer each question even if you do not consider yourself to be 
an active person. 
 




In answering the following questions,  
♦ vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder that normal. 
 
♦ moderate activities refer to activities that take moderate physical effort and 
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1a. During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, aerobics, or fast bicycling,?  
  
 Think about only those physical activities that you did for at least 10 minutes at a time. 
 









2a. Again, think only about those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 








3a. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? This includes walking at work and at home, walking to travel from place to place, 
and any other walking that you did solely for recreation, sport, exercise or leisure.  
 








The last question is about the time you spent sitting on weekdays while at work, at 
home, while doing course work and during leisure time.  This includes time spent 
sitting at a desk, visiting friends, reading traveling on a bus or sitting or lying down to 
watch television.  
 
4. During the last 7 days, how much time in total did you usually spend sitting on a  
 week day? 
 




This is the end of questionnaire, thank you for participating. 
1b. How much time in total did you usually 
spend on one of those days doing 
vigorous physical activities? 
 
_____ hours ______ minutes 
2b. How much time in total did you usually 
spend on one of those days doing 
moderate physical activities? 
 
_____ hours ______ minutes 
3b. How much time in total did you usually 
spend walking on one of those days? 
 
_____ hours ______ minutes 
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Alle svar vil bli behandlet strengtfortrolig.
I dette skjemaet spor vi om dine spisevaner slik de er n6.
Vi er klar over at kostholdet varierer fra dag til dag. Prov derfor
si godt du kan i gi et "gjennomsnitt" av dine spisevaner. Der du
er usikker. ansli svaret.
Skjemaet skal leses av en maskin, og det er derfor viktig at du
setter et tydelig kryss i avmerket rute.
Riktig markering er slik: I
Bruk helst svart eller bli kulepenn (ikke rad).
Blot blyant kan ogsi brukes, men marker da ekstra tydelig.
Av hensyn til den maskinelle lesingen pass p6 at arkene ikke blir brettet.
Eksempel pfl utfylling av sporsmel 1.
Kari Nordmann spiser daglig 5 skiver brqd og ett knekkebrod. Hun
spiser vanligvis kneippbrad, men i helgene blir det en del loff. I
tillegg spiser hun ett knekkebrod hver dag. Hun fzller ut forste
sporsmfll slik:
1. Hvor mye brsd pleier du fl spise?
Legg sammen det du bruker til alle miltider ilapet av en dag.
(1/2 rundstykke: I skive, I baguett: 5 skiver, 1 ciabatta:4 skiver)
Fint brsd
(loff, baguetter, fine rundstykker o.l.)
Mellomgrovt brod
{lys helkorn, lys kneipp, lys hj.bakt o l )
Grovt brsd
(f iberkneion. mork kneinn. morkt hi.  bakt n. l .)
Knekkebrod
(kavring, grov skonrok o.l.)
Sum skiver pr. dag = 6
Antall skiver pr. uke: 6 x 7 : 42. Tallet brukes i sporsmil 5.
Antall skiver pr. dag
n U 2  1  2  3  4  5  E  7  B  g  1 0  1 1  1 2 +
t r t rE I I f t t r nn t r t r t r t r t r t r
N t r t rNEEI t rNDNt r ! t rD
E t rnD t r t r t r n t r n t r n t r t r
t r t rE I t r n ! t r f l t r t r t r t r t r t r
I 1. HVOR MYE BROD PLEIER DU A SPISE?
Fint brod
( lof f ,  baguetter,  f ine rundstykker o. l . )
Mellomgrovt brgd
( l y s  he l ko rn ,  l y s  kne ipp ,  l ys  h j . bak t  o . l . )
2.HVA PLEIER DU A SIVI/RE PA
BRODET?
Merk av bSde for hverdag og helg, selv
om du bruker  det  samme.
Grovt brad
( f i be rkne ipp ,markkne ipp ,m@rk th j . bak to , l . )  I  n  n  !  I  n  !  t r  t r  n  n
Knekkebrgd
(kavr ing ,  g rov  skonrok  o . l . )
Sum sk iver  p r .  dag
Anta l l  sk iver  p r .  uke : x7  =  _ .  Ta l le t  b rukes  i sporsmSl  5 .
Legg sammen det  du bruker t i l  a l le  mSl t ider  i lOpet  av en dag.
(1/2 rundstykke = 1 sk ive,  1 baguet t  = 5 sk iver ,  1 c iabat ta = 4 sk iver)
Antall  skiver pr. dag
ou2 r  2  3  4  5  6  7  B  9
nnrxnnnlrrn
T ITNNTNTIT I
N T I T N f T N N f T T t I N
1 0  1 1  1 2 +
ntr t r
TTN







FETT PA AROO, HVOR
MYE BRUKER DU?
Hverdager
I  Bruker ikke

















En porsjonspakning pE tZ g






n Soft- ,  soyamargarin (pakke, beger)
f  So ls ikke




n Soft  l ight
n Vita tett
I  Annen margar in
4,MELK SOM DRIKK
( 1  g l a s s  =  1 , 5  d l )
Helmelk ,  sot ,  sur
Lettmelk, sot,  sur
Lettmelk, ekstra lett



















Antall glass pr. dag
2 3 4
t rnr
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I
mr
Brun ost,  pr im :
Hvit ost, helfet, 27o/o fett (Jarlsberg,
Norvegia o.1.,  smoreost; eske, tube) I
Hvit ost, halvfet, L6o/o fett (Jarlsberg,
Norvegia o. l .  smoreost ;  eske,  tube)  t r
Ost med mer enn 27o/o fett
(kremoster, Normanna, Ridderost) n
5. PALEGGSSORTER
Bruk sum skiver pr.  uke fra sporsmSl Ti l  antal l  skiver pr.  uke


























Leverpostei,  vanl ig
Leverpostei,  mager
Serve lat ,  vanl ig
Lett servelat,  kalverul l ,
kokt  sk inke,  okseru l l  o . l .
Sa l t  po lse,  spekepolse
( fErepolse,  sa lami  o . l . )
Kav iar
Makrel l  i tomat, rOkt makrel l
















6-7 8-74 75-2] 22-28 29-35 36+
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2-3 4-5 6-7 B-74 75-27 22-28 29-35 36+
nt r InnIDn
x
Gronnsaker  som pBtegg
(agurk ,  tomat  o . l . )
Frukt  som pSlegg (banan,  ep le
Salater  med majones
Majones pE smarbrad
6. EGG




e n n l  1
fn






4l lllll i il]il |il i | ilil]|il]] il]il il]il l|il il ilt1 mr
I7.
Gang pr.  mSned
Havregryn ,kornb land ingero<1  r23
(4 -korn ,uso te tmus l i  o . l . )  r  !  n  n  n
Cornflakes, puffet ris,
havrengtter o. l . nnr! t r
rnnlnHavregrot
Sukker ti l frokostgryn, grat
Yoghurt,  naturel l ,  f rukt
Lettyoghurt
Go'morgen yoghurt,
ink l .  mus l i
Melk  sot ,  sur  pB gryn,
grot og dessert
B. KAFFE OG TE
(1 kopp kaffe = I ,2 dl
FROKOSTGRYN, GR@T OG YOGHURT
Svar  enten pr .  mEned e l ler  pr .  uke.  <1 betyr  s je ldnere enn 1 9ang.
Gang pr .  uke
7 2-3 4-5 6-7 8+
t r t r ! !n (d l )
!n ! t rn (d l )
unr ln (d l )
t r I I I I ( t s )
!  [  n  [  3 (beoe r )
n  n  n  n  n (bege r )
n  n  n  X  3 (be9e r )
f rn t rn(d l )
Mengde pr .  gang
t rt/z 2 3+
n ! t rn





r  1r/2 2 3+
ntr !n
r-2 3-4 s-6 7
nrnn
L 2 3 - 4 5 +
TNNT
r/2 | tL/2 2+
!n t rn
L/2 r tr/2 2+
!nnn
u2 | rr/2 2+
nnrn












Antal l  kopper pr.  dag
dt)
Kaffe, kokt
Kaffe, traktet, fi lter




Sukker ti l kaffe
Sukker t i l  te
Kunstig sgtstoff ti l kaffe eller te
Flote til kaffe
Antall  teskjeer el ler biter pr. kopp


























7  - 8  9 -  1 0  1 1 +
!n t r
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9. ANDRE DRIKKER
Svar  enten pr .  mEned e l ler  pr .  uke.  <  1 betyr  s je ldnere nn 1 gang.  Merk at
porsjonsenhetene er forskjel l ige. 1/3 l i ter t i lsvarer en halvf laske gl og 2/3 l i ter
t i lsvarer  en he l f laske.
mSned
2 3
t r t r
T I
IT













Gang pr .  uke
2-3 4-5 6-7 B+
M n (stass)
n  t r  I  n ( g t a s s )
I  n  f  n ( s t a s s )
Vann
Appels in ju ice
Annen ju ice,  most ,  nektarn
Saft,  solbersirup m.
sukker  r
Saft,  kunst ig sotet r
Brus,  Co la ,  So lo  o . l .
med sukker  r
Brus,  Cola,  Solo o. l .
kunst ig sotet I
Farr is ,  Sel ters ,  Soda o. l .  r
Al koholfr i t t  Al,  v OrterTl,
lettgl













t / 2 7  2  3  4  5 +
t rTNNTt r
I / 2  1 2  3  4  5 +
nrf t r rn
I / 2  I 2  3  4  5 +
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f  t  i ' n l a c c )
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( l i te r )
( l i te r )
(g  lass)
(  1  d ram
=+ct )
I  1 l /2+
TT
I  I I /2+
Ttr
I  7 I / 2 +
TD
I  I I /2+
DI





















Vi  spor  OSOe om middagsm8l t idene og det  du sp iser  t i l  andre mSl t ider ,  Te l l  t i l  s lu t t
sammen anta l l  re t ter  du har  merket  av for  3  se om summen v i rker  sannsynl ig .
En "d l "  t i lsvarer  omtrent  mengden i en suppeose.  Med "ss"  menes en sp isesk je .
Gang pr ,  m8ned Mengde  p r .  gang
Kjottpolse, med isterpolse
Hamburger ,  karbonader  o . l ,
Gr i l l -  og wienerpolse
Ha mbu rger-,  polsebrod,
lomper
Kj@ttka ker, medisterka ker,
kjottpudding
Kjottdeigretter (saus el ler gryte
med k jo t tde ig ,  lasagne o. l . )
Taco (med kjott  og salat)
Pasta retter
TTITTTIT I
t r t r I t rTT IT f
TTTINTt rTT




2  3  4 5 +
TNDI
2  3  4 5 +
TTf t r




























2/3 L rI/2 2+
TT IT
2  3  4 5 +
TDTT
2  3  4 5 +
I TT I
2  3  4 5 +
T !TT
2  3  4 5 +
NTTT
24756
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Pizza (500-600 g)
Bif f  (al le typer kjott)
Kote le t ter  ( lam,  okse,  sv in)
Stek ( lam,  okse,  sv in)
Stek (e lg ,  h jor t ,  re insdyr  o . l . )
Gryterett med helt kjatt,
f r ikassd,  fBr ikSl  o . l .
Lapska us, su ppela pska us,
betasuppe
Bacon, stekt f lesk
Ky l l ing ,  hone
Leverretter
Fiskeka ker, f iskepuddi ng,
med f isk
Reker, krabbe
Risgrot ,  annen melkegrot
Pannekaker
Suppe ( tomat ,  b lomkSl ,
er tesuppe o, l .  )
Vegeta rrett, vegetarpizza,
gronnsaksgrateng,  -pa i
Brun/hv i t  saus
Smel te t  margar in ,  sm@r




Gang pr .  m8ned
0  < 1  r  2  3  4  5 - 6 7 - 8 9 +
I I I I I I I I t r I ( p i z z a )
t r rnrr r r r r (s tk)
t r I t r I t r t r t r t rU(s tk )
IXn I I I I t r t r ( sk ive )
I I I I I I I I [ ( s k i v e )
NTTTT t rTT t ]
Mengde pr .  gang
7/8  t /4 t /2  3 /4  I+
TTNt rT
r /2  L  r r /22  2r /2+
T N I T t r
t / 2  |  r r / 2 2  2 r / 2 +
TXTt rT
I -2  3-4 5-6 7-B 9+
TI t rTT
I -2  3-4 5-6 7-B 9+
t r [ t rTT
I -2  3-4 5-6 7-B 9+
NITT t r
I -2  3-4 5-6 7-B 9+
t rTTTt r
t -2  3-4 5-6 7-B 9+
XTT t ]T
r/4 r/3 r/2 3/4 1+
TTT t rN
1-2 3-4 5-6 7-B 9+
NTIDT
f iskebol ler  r
F iskepinner  r
Torsk, sei,  hyse (kokt) r
Torsk, sei,  hyse (stekt,  panert)r
Sild (fersk, speket, rakt) x tr tr r
Makre l l  ( fersk, rokt )  r  r  r  r




t r t r t r r
I I T I








































r t r t r t r t r
IT t r t ] I
3  4  5 -6  7 -B  9+
Tt rTTT
N I T I T
t rT t ] IT
n f t r t r r
TT I t r t r
t rT ITT
t r t rT t r t r
T I T I N
T T I T I
3  4  5 -6  7 -B 9+
T N T N N
TTTt rT
L-2 3-4 5-6 7-B 9+
I TTN I
l -2  3 -4  5 -6  7 -B 9+
TTTTD
r-2 3-4 5-6 7-B 9+
TTT I f
I -2  3 -4  5 -6  7 -B 9+
T T I f T
r / 2  r  r r / 2 2  2 I / 2 +
I T T T T
24756
I 2 3 4 5 +
I TT I f
t-2 3-4 5-6 7-9 tO+
TTXTT
r  2  3  4  5+
NTNt rT
1 2  3  4  5 +
I T t ]TT
I 2  3  4  5 +
TDTIX
r / 2 t t t / 2 2  3 +
TTNTt r
I 2 3 4 5 +
XDNTN
l -2  3 -4  5 -6  7 -B 9+
N T N I N
I 2 3 4 5 +
Tt rTTt r
NTXTTt r t rTN
TTTI ITNTN





t r t r IT
3 4  5-6  7-8  9+
I T T T N
TT IT I
T ITTN
[ t rTT t ]
fT I IT
l -2  3 -4  5 -6  7 -a  9+
t rTT t rT
I 2 3 4 5 +
I T N I X
I 2 3 4 5 +
! T I N T
r z 5 + ) +
T I f N T
7ililIil ilil ]il ililililil]il il] l] 1] ilil1 ilI il1 fl
11. POTETER, RIS, SPAGHETTI, GR@NNSAKER
Gang pr .  mEned








Spaghett i ,  makaroni ,
pastaxr t r r t r
Gul ro t I t r I I I
HodekSlrurr r
Kl l ro t Ix t r I I
B lomkSl  r t rnr
Brokkol i  r r r l r
RosenkSlnLl t rnn
GrgnnkSl  t r t r r r r
Lakrr r r l
Spinat ,andrebladgronns.  r  r  r  n  n
SoppIDI I I
Avocado I I t r I I
Papr i ka I I rn I
Tomatnr t r r !























Hvor  mange ganger  om dagen sp iser  du van l igv is
gronnsaker  u tenom grgnnsakene du sp iser  t i l  middag?
l lllll i i ilililill ililfl|til ilililill|il ilil i il t1
Svar  enten pr .  mBned e l ler  pr .  uke.  <  1 betyr  s je ldnere nn 1 gang.
Disse sporsm8lene dreier seg forst og fremst om t i lbehgr t i l  middagsretter,  men
spiser  du for  eksempel  en rE gu l ro t  e l ler  sa la t  t i l  luns j ,  ska l  det  tas med her .
Gang  p r .  uke
I 2-3 4-5 6-7 8+ 
1
I I I n I ( s t k ) I
1
r t rnrn(d l )n
Mengde  p r .  gang
1-2
nnrx l (d l ) r
1t2
I I X I I ( s t k ) l
1
I I I I n ( s k a t k ) [
1
!  n  n  [  ! ( s k i ve )n
1 - 2
I  I  I  X  I  (buke t t )3
r_2
I  I  I  I  I  (buket t ) t r
r -2
l l nnn (s t k ) t r
1
L.l  Ll r l  Ll  r l  (dt) t_l
1
T T T I T ( s s ) T
'I
r t rn t r ! (dr ) -
r_2
t r  I  I  n  I ( s t k )  I
r/4
I  I  I  I  I ( s t k )  f ,
1
I  I  I  t r  I ls t r tmmetyE
r/2
I t ] I I t r ( s t k )D
1
T ITT t r (d I )T
r_2





1 2 3 4 5 +
TTT t rT (d I ) ITNT t ]
1-2 3-4 5-6 7_8 9+








IL ln f ] n
t
(d t )  r
1





















































































0 1 2 3 4 5 +
IT t r ITT
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Svar enten pr. mBned e l ler  pr .  uke.  <  1 betyr  s je ldnere nn 1 gang '
Eple




Eksotisk frukt (kiwi,  mango)
Annen frukt ( fersken,





Gang pr .  mSned
0  < 1  1  2  3
I N T N T
I t rT [ t r
TNTNT
rrunn
I I T N I
Gang pr.  uke
r 2-3 4-5 6-7 8+
n I I I n ( s t k )
I n I I n ( s t k )
I n l n I ( s t k )
I I I I n ( k l a s e )
Innn I (s tk )
n I I t r I ( s tk )TX




r t r rn t r (d l )
r rnnr (d l )
T T T T f ( d I )
Mengde pr .  gang
7 / 2  1 2  3 +
Dnf t r
I /2  1 2 3+
nrrn
t / 2 r  2  3+
fNTT
r /2  I  2  3+
NTTN
r /2 r  2  3+
TNTT
r l 2 L  2  3 +
unrx
t / 2 r  2  3 +
nlnn
t / 2 r  2  3 +
r ln l
l / 2 L  2  3 +
T ITX
0 1 2 3 4 5 6 7 8 9 +
N f J N T T I I N N T
24756
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I 14.DESSERT, KAKER, GODTERI
Svar  enten pr .  mEned e l ler  pr .  uke.  <  1 betyr  s je ldnere nn 1 gang.
Hermetisk frukt, fru ktgrot
Puddinger  (s joko lade,
karamel l  o , l . )
Is  (1  d l=1 p inne=1
kremmerhus)
Bol ler ,  ju lekake,  kr ing le
Skolebrgd,  sk i l l ingsbol le
Wienerbr@d, -kr ingle o. l .
Smul t r ing,  formkake
Vafler
Sjokoladekake, blstka ke,
annen fyl t  kake
Sot kjeks, kakekjeks
(Cookies, Bixi t ,  Hob Nobs)
Sjokolade (60 g)
Drops,  lakr is ,  se igmenn o, l .
SmSgodt  (1  hg =  1009)
Potetgul l  (1 pose 1009=7 dl)
Annen snacks (skruer, cr isp,
sa l ts tenger ,  le t tsnacks o. l . )
Peanotter,  andre notter
(1  Pose 1009 = 4 never)
TN!XT
x lnn l








Gang pr ,  mSned
NTTID
nnnnn
Gang pr.  uke
T I IDT (d t )












I  I  (stk)
Mengde  p r .  gang
I-2 3-4 5-6 7+
IXTT
r /2 r  2  3+
NTT t r
l-2 3-4 5-6 7 +
t r t rnn
t/2 3/4 I rr/2+
t rDTT
I -2  3-4 5-6 7+
NTDT
l -2  3-4 5-6 7+
TT IN
24756





N I T I
Tt rNN
t rnrn
I / 2 7  2  3 +
NNTt r
I 2  3 4 +
nr t f
L  2  3 4 +
utrnn
|  2  3 4 +
XTID
t  2  3 4 +
nnrn
t  2  3 4 +
N X I I
|  2  3 4 +
UTt rX
L / 2  1 2  3 +
nnnr






















r  (d l )
t r rn l r (d l )
I I nnn (neve )
L  2  3 4 +
XNTT
















































I 15. KOSTTILSKUDD (bs = barneskje, ts = teskje)
Gang pr .  uke
Bare vinter-
halvSret 0 < 1
nfr
TTT
f [ t r























Mengde pr .  gang
1 t s  1 b s 1 s s
nnn
I 2 +
kapsler  n n
l -2 3-4 5-6 7+






7 2 3 4 +
N T D N
r 2 3 4 +
nrxn
I 2 3 4 +
nt rDn
1 2 3 4 +
ntrxt r
I 2 3 4 +
TNTf
L 2 3 4 +
t rNTT
7 2 3 4 +
nf f r
1 2 3 4 +
Ttr t r t r
1 2 3 4 +
t r ! In















7 2 3 4 +
nrnn
1 2 3 4 +
nnrn
I 2 3 4 +
rnnx
1 2 3 4 +
N T N I
I 2 3 4 +
rTNT
7 2 3 4 +
T I T T
I 2 3 4 +
I I I T











































I I n tablett
I I n tabtett
I I n tabtett
tr tr D tabtett
I I I tablett
2-3 4-5 6-7
I n n tablett
I tr I tablett
I tr I tablett
24756ililil ililililililI ilililililililililililil ililil]|  il|
Hvis  annet ,  hv i lket?
11 ffit
I 16.




6 8 1 0 1 2 7 4 1 6 1 8 2 0 2 2 2 4 2 4
T!N N TNT N NTN! t ]  t r  [  t r  X  T  t r  N  t r  T t r
L7. MENER DU SVARENE I  SPORRESKJEMAET Ja Nei
GIR ET BRUKBART BILDE AV KOSTHOLDET T N
Er det matvarer/produkter du regelmessig bruker, og som ikke er nevnt i  skjemaet?
18. ER DU FORN@YD MED KROPPSVEKTEN DIN SLIK DEN ER NA?
!Ja
! Nei,  jeg onsker 3 slanke meg
tr Nei,  ieg onsker 3 legge pE meg
Omtrent klokken
7 4 1 6 1 8 2 0 2 2 2 4 2 4
! r ! t r t r t rnnIrnrnnr
kaffe, frukt, godteri, snacks m.v.
ruAn SPISER DU pA nvTRDAGER?
HOVEDMAff iOfn som frokost,  formiddagsmat, middag, kvelds.
19. KJONN




Vennligst se etter at du har svart pB al le sporsmSl.
Takk for innsatsen!
24756
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ISBN xxx-xx-xxxx-xxx-x 
 
 
 
 
 
 
